

Scott Kopetz

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2225634/publications.pdf>

Version: 2024-02-01

610
papers

40,834
citations

2797

94
h-index

3321

184
g-index

650
all docs

650
docs citations

650
times ranked

41139
citing authors

#	ARTICLE	IF	CITATIONS
1	The consensus molecular subtypes of colorectal cancer. <i>Nature Medicine</i> , 2015, 21, 1350-1356.	15.2	3,596
2	Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. <i>Lancet Oncology</i> , The, 2017, 18, 1182-1191.	5.1	2,058
3	Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 773-779.	0.8	1,525
4	Improved Survival in Metastatic Colorectal Cancer Is Associated With Adoption of Hepatic Resection and Improved Chemotherapy. <i>Journal of Clinical Oncology</i> , 2009, 27, 3677-3683.	0.8	1,166
5	Towards the introduction of the "Immunoscore"™ in the classification of malignant tumours. <i>Journal of Pathology</i> , 2014, 232, 199-209.	2.1	1,151
6	Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E-Mutated Colorectal Cancer. <i>New England Journal of Medicine</i> , 2019, 381, 1632-1643.	13.9	918
7	Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer. <i>Nature Reviews Cancer</i> , 2017, 17, 79-92.	12.8	686
8	Cancer classification using the Immunoscore: a worldwide task force. <i>Journal of Translational Medicine</i> , 2012, 10, 205.	1.8	676
9	Impact of <i>BRAF</i> mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer. <i>Cancer</i> , 2011, 117, 4623-4632.	2.0	624
10	Phase II Pilot Study of Vemurafenib in Patients With Metastatic <i>BRAF</i> -Mutated Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 4032-4038.	0.8	583
11	Analytical and Clinical Validation of a Digital Sequencing Panel for Quantitative, Highly Accurate Evaluation of Cell-Free Circulating Tumor DNA. <i>PLoS ONE</i> , 2015, 10, e0140712.	1.1	580
12	Pathologic Response to Preoperative Chemotherapy: A New Outcome End Point After Resection of Hepatic Colorectal Metastases. <i>Journal of Clinical Oncology</i> , 2008, 26, 5344-5351.	0.8	548
13	<i>CCAT2</i> , a novel noncoding RNA mapping to 8q24, underlies metastatic progression and chromosomal instability in colon cancer. <i>Genome Research</i> , 2013, 23, 1446-1461.	2.4	526
14	Association of Computed Tomography Morphologic Criteria With Pathologic Response and Survival in Patients Treated With Bevacizumab for Colorectal Liver Metastases. <i>JAMA - Journal of the American Medical Association</i> , 2009, 302, 2338.	3.8	452
15	Phase II Trial of Infusional Fluorouracil, Irinotecan, and Bevacizumab for Metastatic Colorectal Cancer: Efficacy and Circulating Angiogenic Biomarkers Associated With Therapeutic Resistance. <i>Journal of Clinical Oncology</i> , 2010, 28, 453-459.	0.8	440
16	Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO-ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS. <i>Annals of Oncology</i> , 2018, 29, 44-70.	0.6	432
17	Combined <i>BRAF</i> and MEK Inhibition With Dabrafenib and Trametinib in <i>BRAF</i> V600E-Mutant Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 4023-4031.	0.8	430
18	Feasibility of Large-Scale Genomic Testing to Facilitate Enrollment Onto Genomically Matched Clinical Trials. <i>Journal of Clinical Oncology</i> , 2015, 33, 2753-2762.	0.8	372

#	ARTICLE	IF	CITATIONS
19	High Survival Rate After Two-Stage Resection of Advanced Colorectal Liver Metastases: Response-Based Selection and Complete Resection Define Outcome. <i>Journal of Clinical Oncology</i> , 2011, 29, 1083-1090.	0.8	367
20	KRAS-IRF2 Axis Drives Immune Suppression and Immune Therapy Resistance in Colorectal Cancer. <i>Cancer Cell</i> , 2019, 35, 559-572.e7.	7.7	353
21	Disparity of Race Reporting and Representation in Clinical Trials Leading to Cancer Drug Approvals From 2008 to 2018. <i>JAMA Oncology</i> , 2019, 5, e191870.	3.4	348
22	RAS Mutation Status Predicts Survival and Patterns of Recurrence in Patients Undergoing Hepatectomy for Colorectal Liver Metastases. <i>Annals of Surgery</i> , 2013, 258, 619-627.	2.1	312
23	Blood Neutrophil-to-Lymphocyte Ratio Predicts Survival in Patients with Colorectal Liver Metastases Treated with Systemic Chemotherapy. <i>Annals of Surgical Oncology</i> , 2009, 16, 614-622.	0.7	284
24	Use of Research Biopsies in Clinical Trials: Are Risks and Benefits Adequately Discussed?. <i>Journal of Clinical Oncology</i> , 2013, 31, 17-22.	0.8	273
25	Non-V600 BRAF Mutations Define a Clinically Distinct Molecular Subtype of Metastatic Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2017, 35, 2624-2630.	0.8	267
26	Beyond VEGF: Inhibition of the Fibroblast Growth Factor Pathway and Antiangiogenesis. <i>Clinical Cancer Research</i> , 2011, 17, 6130-6139.	3.2	262
27	Right Versus Left Colon Cancer Biology: Integrating the Consensus Molecular Subtypes. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017, 15, 411-419.	2.3	261
28	Platelets and cancer: a casual or causal relationship: revisited. <i>Cancer and Metastasis Reviews</i> , 2014, 33, 231-269.	2.7	258
29	Molecular Biomarkers for the Evaluation of Colorectal Cancer: Guideline From the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and the American Society of Clinical Oncology. <i>Journal of Clinical Oncology</i> , 2017, 35, 1453-1486.	0.8	255
30	Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study. <i>Journal of Clinical Oncology</i> , 2021, 39, 273-284.	0.8	254
31	Resistance to BRAF Inhibition in BRAF-Mutant Colon Cancer Can Be Overcome with PI3K Inhibition or Demethylating Agents. <i>Clinical Cancer Research</i> , 2013, 19, 657-667.	3.2	250
32	Surgical Strategies for Synchronous Colorectal Liver Metastases in 156 Consecutive Patients: Classic, Combined or Reverse Strategy?. <i>Journal of the American College of Surgeons</i> , 2010, 210, 934-941.	0.2	245
33	Genomic Landscape of Cell-Free DNA in Patients with Colorectal Cancer. <i>Cancer Discovery</i> , 2018, 8, 164-173.	7.7	243
34	ALDH Activity Selectively Defines an Enhanced Tumor-Initiating Cell Population Relative to CD133 Expression in Human Pancreatic Adenocarcinoma. <i>PLoS ONE</i> , 2011, 6, e20636.	1.1	241
35	Extended Preoperative Chemotherapy Does Not Improve Pathologic Response and Increases Postoperative Liver Insufficiency After Hepatic Resection for Colorectal Liver Metastases. <i>Annals of Surgical Oncology</i> , 2010, 17, 2870-2876.	0.7	240
36	Immune profiling of human tumors identifies CD73 as a combinatorial target in glioblastoma. <i>Nature Medicine</i> , 2020, 26, 39-46.	15.2	236

#	ARTICLE	IF	CITATIONS
37	How liquid biopsies can change clinical practice in oncology. <i>Annals of Oncology</i> , 2019, 30, 1580-1590.	0.6	231
38	Multicenter retrospective analysis of metastatic colorectal cancer (CRC) with high-level microsatellite instability (MSI-H). <i>Annals of Oncology</i> , 2014, 25, 1032-1038.	0.6	226
39	Classifying Colorectal Cancer by Tumor Location Rather than Sidedness Highlights a Continuum in Mutation Profiles and Consensus Molecular Subtypes. <i>Clinical Cancer Research</i> , 2018, 24, 1062-1072.	3.2	225
40	Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatment. <i>Annals of Oncology</i> , 2015, 26, 731-736.	0.6	223
41	ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectalâ€“Anal Task Forces whitepaper. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 757-770.	12.5	218
42	Clinical and molecular characterization of earlyâ€“onset colorectal cancer. <i>Cancer</i> , 2019, 125, 2002-2010.	2.0	212
43	Phase II Study of Capecitabine and Oxaliplatin for Advanced Adenocarcinoma of the Small Bowel and Ampulla of Vater. <i>Journal of Clinical Oncology</i> , 2009, 27, 2598-2603.	0.8	208
44	Antitumor Activity of BRAF Inhibitor Vemurafenib in Preclinical Models of BRAF-Mutant Colorectal Cancer. <i>Cancer Research</i> , 2012, 72, 779-789.	0.4	199
45	Epithelialâ€“Mesenchymal Transitioned Circulating Tumor Cells Capture for Detecting Tumor Progression. <i>Clinical Cancer Research</i> , 2015, 21, 899-906.	3.2	199
46	Biomarker-guided therapy for colorectal cancer: strength in complexity. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 11-32.	12.5	195
47	Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with <i>BRAF</i> V600E Mutation. <i>Cancer Discovery</i> , 2016, 6, 1352-1365.	7.7	192
48	Single-cell DNA sequencing reveals a late-dissemination model in metastatic colorectal cancer. <i>Genome Research</i> , 2017, 27, 1287-1299.	2.4	189
49	Oxaliplatin-Mediated Increase in Spleen Size As a Biomarker for the Development of Hepatic Sinusoidal Injury. <i>Journal of Clinical Oncology</i> , 2010, 28, 2549-2555.	0.8	188
50	Binimetinib, Encorafenib, and Cetuximab Triplet Therapy for Patients With <i>BRAF</i> V600Eâ€“Mutant Metastatic Colorectal Cancer: Safety Lead-In Results From the Phase III BEACON Colorectal Cancer Study. <i>Journal of Clinical Oncology</i> , 2019, 37, 1460-1469.	0.8	188
51	Optimal Morphologic Response to Preoperative Chemotherapy: An Alternate Outcome End Point Before Resection of Hepatic Colorectal Metastases. <i>Journal of Clinical Oncology</i> , 2012, 30, 4566-4572.	0.8	187
52	PLX4032 in metastatic colorectal cancer patients with mutant BRAF tumors.. <i>Journal of Clinical Oncology</i> , 2010, 28, 3534-3534.	0.8	177
53	Preoperative Bevacizumab Does Not Significantly Increase Postoperative Complication Rates in Patients Undergoing Hepatic Surgery for Colorectal Cancer Liver Metastases. <i>Journal of Clinical Oncology</i> , 2008, 26, 5254-5260.	0.8	173
54	Meta-analysis of <i>KRAS</i> mutations and survival after resection of colorectal liver metastases. <i>British Journal of Surgery</i> , 2015, 102, 1175-1183.	0.1	171

#	ARTICLE	IF	CITATIONS
55	Anti-EGFR-resistant clones decay exponentially after progression: implications for anti-EGFR re-challenge. <i>Annals of Oncology</i> , 2019, 30, 243-249.	0.6	170
56	Margin Status Remains an Important Determinant of Survival After Surgical Resection of Colorectal Liver Metastases in the Era of Modern Chemotherapy. <i>Annals of Surgery</i> , 2013, 257, 1079-1088.	2.1	169
57	Molecular Profiling of Patient-Matched Brain and Extracranial Melanoma Metastases Implicates the PI3K Pathway as a Therapeutic Target. <i>Clinical Cancer Research</i> , 2014, 20, 5537-5546.	3.2	169
58	Randomized Trial of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF-Mutant Metastatic Colorectal Cancer (SWOG S1406). <i>Journal of Clinical Oncology</i> , 2021, 39, 285-294.	0.8	169
59	A Decision Support Framework for Genomically Informed Investigational Cancer Therapy. <i>Journal of the National Cancer Institute</i> , 2015, 107, .	3.0	168
60	<i>Streptococcus gallolyticus</i> subsp. <i>gallolyticus</i> promotes colorectal tumor development. <i>PLoS Pathogens</i> , 2017, 13, e1006440.	2.1	168
61	Return to intended oncologic treatment (RIOT): A novel metric for evaluating the quality of oncosurgical therapy for malignancy. <i>Journal of Surgical Oncology</i> , 2014, 110, 107-114.	0.8	166
62	Topoisomerase III α in chromosome instability and personalized cancer therapy. <i>Oncogene</i> , 2015, 34, 4019-4031.	2.6	166
63	The Promise of Patient-Derived Xenografts: The Best Laid Plans of Mice and Men. <i>Clinical Cancer Research</i> , 2012, 18, 5160-5162.	3.2	156
64	Potential role of nuclear PD-L1 expression in cell-surface vimentin positive circulating tumor cells as a prognostic marker in cancer patients. <i>Scientific Reports</i> , 2016, 6, 28910.	1.6	152
65	Validation of Microsatellite Instability Detection Using a Comprehensive Plasma-Based Genotyping Panel. <i>Clinical Cancer Research</i> , 2019, 25, 7035-7045.	3.2	152
66	Non-coding RNAs in GI cancers: from cancer hallmarks to clinical utility. <i>Gut</i> , 2020, 69, 748-763.	6.1	152
67	Incidental germline variants in 1000 advanced cancers on a prospective somatic genomic profiling protocol. <i>Annals of Oncology</i> , 2016, 27, 795-800.	0.6	150
68	Systemic Chemotherapy and Two-Stage Hepatectomy for Extensive Bilateral Colorectal Liver Metastases: Perioperative Safety and Survival. <i>Journal of Gastrointestinal Surgery</i> , 2007, 11, 1498-1505.	0.9	149
69	Sotorasib for previously treated colorectal cancers with KRASG12C mutation (CodeBreak100): a prespecified analysis of a single-arm, phase 2 trial. <i>Lancet Oncology</i> , The, 2022, 23, 115-124.	5.1	147
70	Oncogenic <i>Kras</i> drives invasion and maintains metastases in colorectal cancer. <i>Genes and Development</i> , 2017, 31, 370-382.	2.7	137
71	Synergistic Activity of the Src Family Kinase Inhibitor Dasatinib and Oxaliplatin in Colon Carcinoma Cells Is Mediated by Oxidative Stress. <i>Cancer Research</i> , 2009, 69, 3842-3849.	0.4	133
72	BRAF mutant colorectal cancer as a distinct subset of colorectal cancer: clinical characteristics, clinical behavior, and response to targeted therapies. <i>Journal of Gastrointestinal Oncology</i> , 2015, 6, 660-7.	0.6	128

#	ARTICLE	IF	CITATIONS
73	Significant Association of Oncogene YAP1 with Poor Prognosis and Cetuximab Resistance in Colorectal Cancer Patients. <i>Clinical Cancer Research</i> , 2015, 21, 357-364.	3.2	127
74	Platelet "first responders" in wound response, cancer, and metastasis. <i>Cancer and Metastasis Reviews</i> , 2017, 36, 199-213.	2.7	127
75	Liquid Biopsies Using Plasma Exosomal Nucleic Acids and Plasma Cell-Free DNA Compared with Clinical Outcomes of Patients with Advanced Cancers. <i>Clinical Cancer Research</i> , 2018, 24, 181-188.	3.2	127
76	Mutation Status of <i>RAS</i> , <i>TP53</i> , and <i>SMAD4</i> is Superior to Mutation Status of <i>RAS</i> Alone for Predicting Prognosis after Resection of Colorectal Liver Metastases. <i>Clinical Cancer Research</i> , 2019, 25, 5843-5851.	3.2	127
77	A Population-Based Comparison of Adenocarcinoma of the Large and Small Intestine: Insights Into a Rare Disease. <i>Annals of Surgical Oncology</i> , 2012, 19, 1439-1445.	0.7	124
78	Cytokine profile and prognostic significance of high neutrophil-lymphocyte ratio in colorectal cancer. <i>British Journal of Cancer</i> , 2015, 112, 1088-1097.	2.9	123
79	Characterization of immune responses to anti-PD-1 mono and combination immunotherapy in hematopoietic humanized mice implanted with tumor xenografts. , 2019, 7, 37.		123
80	Deleterious Effect of <i>RAS</i> and Evolutionary High-risk <i>TP53</i> Double Mutation in Colorectal Liver Metastases. <i>Annals of Surgery</i> , 2019, 269, 917-923.	2.1	121
81	<i>RAS</i> Mutation Predicts Positive Resection Margins and Narrower Resection Margins in Patients Undergoing Resection of Colorectal Liver Metastases. <i>Annals of Surgical Oncology</i> , 2016, 23, 2635-2643.	0.7	119
82	Genomic landscape associated with potential response to anti-CTLA-4 treatment in cancers. <i>Nature Communications</i> , 2017, 8, 1050.	5.8	115
83	PRMT1-mediated methylation of the EGF receptor regulates signaling and cetuximab response. <i>Journal of Clinical Investigation</i> , 2015, 125, 4529-4543.	3.9	114
84	Immunophenotype and molecular characterisation of adenocarcinoma of the small intestine. <i>British Journal of Cancer</i> , 2010, 102, 144-150.	2.9	112
85	The clinical and biological significance of MIR-224 expression in colorectal cancer metastasis. <i>Gut</i> , 2016, 65, 977-989.	6.1	111
86	Chemotherapy with 5-fluorouracil and a platinum compound improves outcomes in metastatic small bowel adenocarcinoma. <i>Cancer</i> , 2008, 113, 2038-2045.	2.0	109
87	Genomic Classifier ColoPrint Predicts Recurrence in Stage II Colorectal Cancer Patients More Accurately Than Clinical Factors. <i>Oncologist</i> , 2015, 20, 127-133.	1.9	109
88	Progression-Free Survival Remains Poor Over Sequential Lines of Systemic Therapy in Patients With BRAF-Mutated Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2014, 13, 164-171.	1.0	108
89	Molecular Biomarkers for the Evaluation of Colorectal Cancer. <i>Journal of Molecular Diagnostics</i> , 2017, 19, 187-225.	1.2	108
90	The Association of Alternate VEGF Ligands with Resistance to Anti-VEGF Therapy in Metastatic Colorectal Cancer. <i>PLoS ONE</i> , 2013, 8, e77117.	1.1	106

#	ARTICLE	IF	CITATIONS
91	5-Fluorouracil resistant colon cancer cells are addicted to OXPHOS to survive and enhance stem-like traits. <i>Oncotarget</i> , 2015, 6, 41706-41721.	0.8	103
92	Src Continues Aging: Current and Future Clinical Directions. <i>Clinical Cancer Research</i> , 2007, 13, 7232-7236.	3.2	102
93	Deep sequencing of circulating tumor DNA detects molecular residual disease and predicts recurrence in gastric cancer. <i>Cell Death and Disease</i> , 2020, 11, 346.	2.7	102
94	Efficacy of the combination of MEK and CDK4/6 inhibitors <i>in vitro</i> and <i>in vivo</i> in KRAS mutant colorectal cancer models. <i>Oncotarget</i> , 2016, 7, 39595-39608.	0.8	101
95	Long-Term Survival and Recurrence Outcomes Following Surgery for Distal Rectal Cancer. <i>Annals of Surgical Oncology</i> , 2010, 17, 2863-2869.	0.7	100
96	Randomized trial of irinotecan and cetuximab with or without vemurafenib in <i>BRAF</i> -mutant metastatic colorectal cancer (SWOG 1406).. <i>Journal of Clinical Oncology</i> , 2017, 35, 520-520.	0.8	100
97	Efficacy of Sym004 in Patients With Metastatic Colorectal Cancer With Acquired Resistance to Anti-EGFR Therapy and Molecularly Selected by Circulating Tumor DNA Analyses. <i>JAMA Oncology</i> , 2018, 4, e175245.	3.4	98
98	N-BLR, a primate-specific non-coding transcript leads to colorectal cancer invasion and migration. <i>Genome Biology</i> , 2017, 18, 98.	3.8	97
99	Portal Hypertension Associated With Oxaliplatin Administration: Clinical Manifestations of Hepatic Sinusoidal Injury. <i>Clinical Colorectal Cancer</i> , 2009, 8, 225-230.	1.0	94
100	Local tumour progression after percutaneous ablation of colorectal liver metastases according to <i>RAS</i> mutation status. <i>British Journal of Surgery</i> , 2017, 104, 760-768.	0.1	91
101	<i>RAS</i> Mutations Predict Radiologic and Pathologic Response in Patients Treated with Chemotherapy Before Resection of Colorectal Liver Metastases. <i>Annals of Surgical Oncology</i> , 2015, 22, 834-842.	0.7	90
102	Nivolumab ± ipilimumab in treatment (tx) of patients (pts) with metastatic colorectal cancer (mCRC) with and without high microsatellite instability (MSI-H): CheckMate-142 interim results.. <i>Journal of Clinical Oncology</i> , 2016, 34, 3501-3501.	0.8	90
103	Characteristics and outcomes of dementia residents in an assisted living facility. <i>International Journal of Geriatric Psychiatry</i> , 2000, 15, 586-593.	1.3	86
104	Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies. <i>Oncotarget</i> , 2015, 6, 12809-12821.	0.8	86
105	Clinical Actionability Enhanced through Deep Targeted Sequencing of Solid Tumors. <i>Clinical Chemistry</i> , 2015, 61, 544-553.	1.5	85
106	Recent developments in the treatment of metastatic colorectal cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2017, 9, 551-564.	1.4	82
107	Association of CpG island methylator phenotype and EREG/AREG methylation and expression in colorectal cancer. <i>British Journal of Cancer</i> , 2016, 114, 1352-1361.	2.9	81
108	Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142. <i>Annals of Oncology</i> , 2022, 33, 1052-1060.	0.6	81

#	ARTICLE	IF	CITATIONS
109	Association between KRAS mutation and lung metastasis in advanced colorectal cancer. <i>British Journal of Cancer</i> , 2015, 112, 424-428.	2.9	80
110	Predictors of Safety and Efficacy of 2-Stage Hepatectomy for Bilateral Colorectal Liver Metastases. <i>Journal of the American College of Surgeons</i> , 2016, 223, 99-108.	0.2	80
111	Is there a role for adjuvant therapy in resected adenocarcinoma of the small intestine. <i>Acta Oncologica</i> , 2010, 49, 474-479.	0.8	79
112	<i>BRAF</i> Mutation Testing in Cell-Free DNA from the Plasma of Patients with Advanced Cancers Using a Rapid, Automated Molecular Diagnostics System. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 1397-1404.	1.9	78
113	Evidence for the efficacy of Iniparib, a PARP-1 inhibitor, in BRCA2-associated pancreatic cancer. <i>Anticancer Research</i> , 2011, 31, 1417-20.	0.5	78
114	Src family kinases as mediators of endothelial permeability: effects on inflammation and metastasis. <i>Cell and Tissue Research</i> , 2009, 335, 249-259.	1.5	77
115	Therapeutic Silencing of KRAS Using Systemically Delivered siRNAs. <i>Molecular Cancer Therapeutics</i> , 2014, 13, 2876-2885.	1.9	77
116	Mechanisms of Innate and Acquired Resistance to Anti-EGFR Therapy: A Review of Current Knowledge with a Focus on Rechallenge Therapies. <i>Clinical Cancer Research</i> , 2019, 25, 6899-6908.	3.2	76
117	Molecular Biomarkers for the Evaluation of Colorectal Cancer: Guideline From the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and American Society of Clinical Oncology. <i>Archives of Pathology and Laboratory Medicine</i> , 2017, 141, 625-657.	1.2	75
118	The Long Noncoding RNA CCAT2 Induces Chromosomal Instability Through BOP1-AURKB Signaling. <i>Gastroenterology</i> , 2020, 159, 2146-2162.e33.	0.6	75
119	Phase 1 study of TAS-102 administered once daily on a 5-day-per-week schedule in patients with solid tumors. <i>Investigational New Drugs</i> , 2008, 26, 445-454.	1.2	74
120	Prognostic gene expression signature associated with two molecularly distinct subtypes of colorectal cancer. <i>Gut</i> , 2012, 61, 1291-1298.	6.1	74
121	Examining plasma microRNA markers for colorectal cancer at different stages. <i>Oncotarget</i> , 2016, 7, 11434-11449.	0.8	74
122	Perioperative chemotherapy for resectable hepatic metastases. <i>Lancet</i> , The, 2008, 371, 963-965.	6.3	71
123	The Src Family of Protein Tyrosine Kinases: A New and Promising Target for Colorectal Cancer Therapy. <i>Clinical Colorectal Cancer</i> , 2010, 9, 89-94.	1.0	71
124	Hotspot Mutation Panel Testing Reveals Clonal Evolution in a Study of 265 Paired Primary and Metastatic Tumors. <i>Clinical Cancer Research</i> , 2015, 21, 2644-2651.	3.2	70
125	Circulating DNA Demonstrates Convergent Evolution and Common Resistance Mechanisms during Treatment of Colorectal Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 4578-4591.	3.2	70
126	<i>FBXW7</i> missense mutation: a novel negative prognostic factor in metastatic colorectal adenocarcinoma. <i>Oncotarget</i> , 2017, 8, 39268-39279.	0.8	69

#	ARTICLE	IF	CITATIONS
127	Proteome Instability Is a Therapeutic Vulnerability in Mismatch Repair-Deficient Cancer. <i>Cancer Cell</i> , 2020, 37, 371-386.e12.	7.7	68
128	Combined Targeting of STAT3/NF- κ B/COX-2/EP4 for Effective Management of Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2014, 20, 1259-1273.	3.2	67
129	Tumor Thickness at the Tumor-normal Interface: A Novel Pathologic Indicator of Chemotherapy Response in Hepatic Colorectal Metastases. <i>American Journal of Surgical Pathology</i> , 2010, 34, 1287-1294.	2.1	66
130	Is Complete Liver Resection Without Resection of Synchronous Lung Metastases Justified?. <i>Annals of Surgical Oncology</i> , 2015, 22, 1585-1592.	0.7	66
131	Association of SMAD4 mutation with patient demographics, tumor characteristics, and clinical outcomes in colorectal cancer. <i>PLoS ONE</i> , 2017, 12, e0173345.	1.1	65
132	FXR silencing in human colon cancer by DNA methylation and KRAS signaling. <i>American Journal of Physiology - Renal Physiology</i> , 2014, 306, G48-G58.	1.6	64
133	TMEM9 promotes intestinal tumorigenesis through vacuolar-ATPase-activated Wnt/ β 2-catenin signalling. <i>Nature Cell Biology</i> , 2018, 20, 1421-1433.	4.6	64
134	Phase I Clinical Study of Three Times a Day Oral Administration of TAS-102 in Patients with Solid Tumors. <i>Cancer Investigation</i> , 2008, 26, 794-799.	0.6	62
135	Adjuvant Chemotherapy With FOLFOX for Primary Colorectal Cancer Is Associated With Increased Somatic Gene Mutations and Inferior Survival in Patients Undergoing Hepatectomy for Metachronous Liver Metastases. <i>Annals of Surgery</i> , 2012, 256, 642-650.	2.1	62
136	Circulating tumor markers: harmonizing the yin and yang of CTCs and ctDNA for precision medicine. <i>Annals of Oncology</i> , 2017, 28, 468-477.	0.6	62
137	Impact of Recurrence and Salvage Surgery on Survival After Multidisciplinary Treatment of Rectal Cancer. <i>Journal of Clinical Oncology</i> , 2017, 35, 2631-2638.	0.8	62
138	Immune Profiling of Premalignant Lesions in Patients With Lynch Syndrome. <i>JAMA Oncology</i> , 2018, 4, 1085.	3.4	62
139	Platelets, circulating tumor cells, and the circulome. <i>Cancer and Metastasis Reviews</i> , 2017, 36, 235-248.	2.7	61
140	SMAD4 gene mutation predicts poor prognosis in patients undergoing resection for colorectal liver metastases. <i>European Journal of Surgical Oncology</i> , 2018, 44, 684-692.	0.5	61
141	Biomarkers in colorectal liver metastases. <i>British Journal of Surgery</i> , 2018, 105, 618-627.	0.1	59
142	Embryonic Origin of Primary Colon Cancer Predicts Pathologic Response and Survival in Patients Undergoing Resection for Colon Cancer Liver Metastases. <i>Annals of Surgery</i> , 2018, 267, 514-520.	2.1	59
143	HER2 amplification as a negative predictive biomarker for anti-epidermal growth factor receptor antibody therapy in metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, 3517-3517.	0.8	59
144	Comprehensive characterization of 536 patient-derived xenograft models prioritizes candidates for targeted treatment. <i>Nature Communications</i> , 2021, 12, 5086.	5.8	58

#	ARTICLE	IF	CITATIONS
145	Metastasis regulation by PPAR δ expression in cancer cells. JCI Insight, 2017, 2, e91419.	2.3	58
146	Expanded KRAS: Refining the Patient Population. Journal of Clinical Oncology, 2015, 33, 682-685.	0.8	57
147	Clinical, Pathological, and Molecular Characteristics of CpG Island Methylator Phenotype in Colorectal Cancer: A Systematic Review and Meta-analysis. Translational Oncology, 2018, 11, 1188-1201.	1.7	57
148	Relative Abundance of SARS-CoV-2 Entry Genes in the Enterocytes of the Lower Gastrointestinal Tract. Genes, 2020, 11, 645.	1.0	57
149	Pathological Tumor Response Following Immune Checkpoint Blockade for Deficient Mismatch Repair Advanced Colorectal Cancer. Journal of the National Cancer Institute, 2021, 113, 208-211.	3.0	56
150	Sacral Insufficiency Fractures After Preoperative Chemoradiation for Rectal Cancer: Incidence, Risk Factors, and Clinical Course. International Journal of Radiation Oncology Biology Physics, 2009, 74, 818-823.	0.4	55
151	Conditional Recurrence-Free Survival after Resection of Colorectal Liver Metastases: Persistent Deleterious Association with RAS and TP53 Co-Mutation. Journal of the American College of Surgeons, 2019, 229, 286-294.e1.	0.2	55
152	BRAF Inhibitors: Experience in Thyroid Cancer and General Review of Toxicity. Hormones and Cancer, 2015, 6, 21-36.	4.9	54
153	MET amplification in metastatic colorectal cancer: an acquired response to EGFR inhibition, not a de novo phenomenon. Oncotarget, 2016, 7, 54627-54631.	0.8	53
154	Mutation-Enrichment Next-Generation Sequencing for Quantitative Detection of KRAS Mutations in Urine Cell-Free DNA from Patients with Advanced Cancers. Clinical Cancer Research, 2017, 23, 3657-3666.	3.2	53
155	Molecular Landscape of ERBB2/ERBB3 Mutated Colorectal Cancer. Journal of the National Cancer Institute, 2018, 110, 1409-1417.	3.0	53
156	Patient-derived micro-organospheres enable clinical precision oncology. Cell Stem Cell, 2022, 29, 905-917.e6.	5.2	53
157	Quantified pathologic response assessed as residual tumor burden is a predictor of recurrence-free survival in patients with rectal cancer who undergo resection after neoadjuvant chemoradiotherapy. Cancer, 2013, 119, 4231-4241.	2.0	52
158	The somatic mutation landscape of premalignant colorectal adenoma. Gut, 2018, 67, 1299-1305.	6.1	52
159	Global and targeted serum metabolic profiling of colorectal cancer progression. Cancer, 2017, 123, 4066-4074.	2.0	51
160	Clinical Findings of a Palliative Care Consultation Team at a Comprehensive Cancer Center. Journal of Palliative Medicine, 2008, 11, 191-197.	0.6	50
161	Individualized therapies in colorectal cancer: KRAS as a marker for response to EGFR-targeted therapy. Journal of Hematology and Oncology, 2009, 2, 18.	6.9	50
162	Gene Expression Profiling of Ampullary Carcinomas Classifies Ampullary Carcinomas into Biliary-Like and Intestinal-Like Subtypes That Are Prognostic of Outcome. PLoS ONE, 2013, 8, e65144.	1.1	50

#	ARTICLE	IF	CITATIONS
163	Dual Inhibition of EGFR and c-Src by Cetuximab and Dasatinib Combined with FOLFOX Chemotherapy in Patients with Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 4146-4154.	3.2	50
164	Development and Validation of an Ultradeep Next-Generation Sequencing Assay for Testing of Plasma Cell-Free DNA from Patients with Advanced Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 5648-5656.	3.2	50
165	Is hepatectomy justified for patients with RAS mutant colorectal liver metastases? An analysis of 524 patients undergoing curative liver resection. <i>Surgery</i> , 2017, 161, 332-340.	1.0	50
166	Back to the Colorectal Cancer Consensus Molecular Subtype Future. <i>Current Gastroenterology Reports</i> , 2019, 21, 5.	1.1	50
167	Extended RAS analysis for anti-epidermal growth factor therapy in patients with metastatic colorectal cancer. <i>Cancer Treatment Reviews</i> , 2015, 41, 653-659.	3.4	49
168	Impact of multimodal therapy in locally recurrent rectal cancer. <i>British Journal of Surgery</i> , 2016, 103, 753-762.	0.1	49
169	Nivolumab in patients with DNA mismatch repair deficient/microsatellite instability high metastatic colorectal cancer: Update from CheckMate 142.. <i>Journal of Clinical Oncology</i> , 2017, 35, 519-519.	0.8	49
170	Predictive and Prognostic Markers in Colorectal Cancer. <i>Current Oncology Reports</i> , 2011, 13, 206-215.	1.8	48
171	Partial splenic embolization for cancer patients with thrombocytopenia requiring systemic chemotherapy. <i>Cancer</i> , 2008, 112, 2283-2288.	2.0	47
172	Durable Complete Responses in Metastatic Colorectal Cancer Treated with Chemotherapy Alone. <i>Clinical Colorectal Cancer</i> , 2011, 10, 178-182.	1.0	47
173	Clinicopathologic characteristics and gene expression analyses of non-KRAS 12/13, RAS-mutated metastatic colorectal cancer. <i>Annals of Oncology</i> , 2014, 25, 2008-2014.	0.6	47
174	Genome-wide Discovery and Identification of a Novel miRNA Signature for Recurrence Prediction in Stage II and III Colorectal Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 3867-3877.	3.2	47
175	Circulating Tumor DNA—Defined Minimal Residual Disease in Solid Tumors: Opportunities to Accelerate the Development of Adjuvant Therapies. <i>Journal of Clinical Oncology</i> , 2018, 36, 3437-3440.	0.8	47
176	MicroRNAs, ultraconserved genes and colorectal cancers. <i>International Journal of Biochemistry and Cell Biology</i> , 2010, 42, 1291-1297.	1.2	46
177	GWAS-identified colorectal cancer susceptibility loci associated with clinical outcomes. <i>Carcinogenesis</i> , 2012, 33, 1327-1331.	1.3	46
178	Validation of HER2 Amplification as a Predictive Biomarker for Anti-Epidermal Growth Factor Receptor Antibody Therapy in Metastatic Colorectal Cancer. <i>JCO Precision Oncology</i> , 2019, 3, 1-13.	1.5	46
179	Endothelial Function, Oxidative Stress and Inflammatory Studies in Chronic Coronary Slow Flow Phenomenon Patients. <i>Cardiology</i> , 2012, 121, 197-203.	0.6	45
180	Hyperfractionated accelerated reirradiation for rectal cancer: An analysis of outcomes and toxicity. <i>Radiotherapy and Oncology</i> , 2017, 122, 146-151.	0.3	45

#	ARTICLE	IF	CITATIONS
181	Bevacizumab combined with capecitabine and oxaliplatin in patients with advanced adenocarcinoma of the small bowel or ampulla of vater: A single-center, open-label, phase 2 study. <i>Cancer</i> , 2017, 123, 1011-1017.	2.0	45
182	<i>BRAF</i> mutation testing with a rapid, fully integrated molecular diagnostics system. <i>Oncotarget</i> , 2015, 6, 26886-26894.	0.8	45
183	Molecular spectrum of KRAS, NRAS, BRAF, PIK3CA, TP53, and APC somatic gene mutations in Arab patients with colorectal cancer: determination of frequency and distribution pattern. <i>Journal of Gastrointestinal Oncology</i> , 2016, 7, 882-902.	0.6	44
184	Postoperative chemotherapy use after neoadjuvant chemoradiotherapy for rectal cancer: Analysis of Surveillance, Epidemiology, and End Results—Medicare data, 1998–2007. <i>Cancer</i> , 2014, 120, 1162-1170.	2.0	43
185	Retreatment with anti-EGFR based therapies in metastatic colorectal cancer: impact of intervening time interval and prior anti-EGFR response. <i>BMC Cancer</i> , 2015, 15, 713.	1.1	43
186	Target-Based Therapeutic Matching in Early-Phase Clinical Trials in Patients with Advanced Colorectal Cancer and <i>PIK3CA</i> Mutations. <i>Molecular Cancer Therapeutics</i> , 2013, 12, 2857-2863.	1.9	42
187	Phase I/II study of azacitidine and capecitabine/oxaliplatin (CAPOX) in refractory CIMP-high metastatic colorectal cancer: evaluation of circulating methylated vimentin. <i>Oncotarget</i> , 2016, 7, 67495-67506.	0.8	42
188	Randomized trial of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (SWOG S1406).. <i>Journal of Clinical Oncology</i> , 2017, 35, 3505-3505.	0.8	42
189	High-Grade Neuroendocrine Colorectal Carcinomas: A Retrospective Study of 100 Patients. <i>Clinical Colorectal Cancer</i> , 2016, 15, e1-e7.	1.0	41
190	MultiplexKRASG12/G13 mutation testing of unamplified cell-free DNA from the plasma of patients with advanced cancers using droplet digital polymerase chain reaction. <i>Annals of Oncology</i> , 2017, 28, 642-650.	0.6	41
191	Modeling of Patient-Derived Xenografts in Colorectal Cancer. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 1435-1442.	1.9	40
192	Prevalence of recurrent oncogenic fusion in mismatch repair-deficient colorectal carcinoma with hypermethylated MLH1 and wild-type BRAF and KRAS. <i>Modern Pathology</i> , 2019, 32, 1053-1064.	2.9	40
193	Intratumoral heterogeneity: Role of differentiation in a potentially lethal phenotype of testicular cancer. <i>Cancer</i> , 2016, 122, 1836-1843.	2.0	39
194	Phase II study of nab-paclitaxel in refractory small bowel adenocarcinoma and CpG island methylator phenotype (CIMP)-high colorectal cancer. <i>Annals of Oncology</i> , 2018, 29, 139-144.	0.6	39
195	Nivolumab in patients with DNA mismatch repair-deficient/microsatellite instability-high (dMMR/MSI-H) metastatic colorectal cancer (mCRC): Long-term survival according to prior line of treatment from CheckMate-142.. <i>Journal of Clinical Oncology</i> , 2018, 36, 554-554.	0.8	39
196	Multicenter validation study of pathologic response and tumor thickness at the tumor-normal liver interface as independent predictors of disease-free survival after preoperative chemotherapy and surgery for colorectal liver metastases. <i>Cancer</i> , 2013, 119, 2778-2788.	2.0	38
197	Blood-Based Tests for Colorectal Cancer Screening: Do They Threaten the Survival of the FIT Test?. <i>Digestive Diseases and Sciences</i> , 2015, 60, 664-671.	1.1	38
198	First in human phase I study of BSI-201, a small molecule inhibitor of poly ADP-ribose polymerase (PARP) in subjects with advanced solid tumors. <i>Journal of Clinical Oncology</i> , 2008, 26, 3577-3577.	0.8	38

#	ARTICLE	IF	CITATIONS
199	Phase II study of saracatinib (AZD0530) in patients with previously treated metastatic colorectal cancer. <i>Investigational New Drugs</i> , 2015, 33, 977-984.	1.2	37
200	The potential role of platelets in the consensus molecular subtypes of colorectal cancer. <i>Cancer and Metastasis Reviews</i> , 2017, 36, 273-288.	2.7	37
201	Efficacy, Safety, and Biomarker Analysis of Combined PD-L1 (Atezolizumab) and VEGF (Bevacizumab) Blockade in Advanced Malignant Peritoneal Mesothelioma. <i>Cancer Discovery</i> , 2021, 11, 2738-2747.	7.7	37
202	New therapies and insights into the changing landscape of colorectal cancer. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2019, 16, 79-80.	8.2	36
203	A <i>NOTCH1</i> gene copy number gain is a prognostic indicator of worse survival and a predictive biomarker to a Notch1 targeting antibody in colorectal cancer. <i>International Journal of Cancer</i> , 2016, 138, 195-205.	2.3	35
204	Severe obesity prior to diagnosis limits survival in colorectal cancer patients evaluated at a large cancer centre. <i>British Journal of Cancer</i> , 2016, 114, 103-109.	2.9	35
205	RAS Mutation Is Associated with Decreased Survival in Patients Undergoing Repeat Hepatectomy for Colorectal Liver Metastases. <i>Journal of Gastrointestinal Surgery</i> , 2017, 21, 68-77.	0.9	35
206	Colorectal premalignancy is associated with consensus molecular subtypes 1 and 2. <i>Annals of Oncology</i> , 2018, 29, 2061-2067.	0.6	35
207	Encorafenib plus cetuximab with or without binimetinib for <i>BRAF</i> V600E metastatic colorectal cancer: Updated survival results from a randomized, three-arm, phase III study versus choice of either irinotecan or FOLFIRI plus cetuximab (BEACON CRC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 4001-4001.	0.8	35
208	Can Microsatellite Status of Colorectal Cancer Be Reliably Assessed after Neoadjuvant Therapy?. <i>Clinical Cancer Research</i> , 2017, 23, 5246-5254.	3.2	34
209	Prognostic Implications of Mucinous Differentiation in Metastatic Colorectal Carcinoma Can Be Explained by Distinct Molecular and Clinicopathologic Characteristics. <i>Clinical Colorectal Cancer</i> , 2018, 17, e699-e709.	1.0	34
210	Current and Future Horizons of Patient-Derived Xenograft Models in Colorectal Cancer Translational Research. <i>Cancers</i> , 2019, 11, 1321.	1.7	34
211	Colorectal Cancer Subtyping Consortium (CRCSC) identification of a consensus of molecular subtypes.. <i>Journal of Clinical Oncology</i> , 2014, 32, 3511-3511.	0.8	34
212	KRASG12C-independent feedback activation of wild-type RAS constrains KRASG12C inhibitor efficacy. <i>Cell Reports</i> , 2022, 39, 110993.	2.9	34
213	Combining Neratinib with CDK4/6, mTOR, and MEK Inhibitors in Models of HER2-positive Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 1681-1694.	3.2	33
214	Impact of Circulating Tumor DNA-Based Detection of Molecular Residual Disease on the Conduct and Design of Clinical Trials for Solid Tumors. <i>JCO Precision Oncology</i> , 2022, 6, e2100181.	1.5	33
215	CT Findings of Response and Recurrence, Independent of Change in Tumor Size, in Colorectal Liver Metastasis Treated With Bevacizumab. <i>American Journal of Roentgenology</i> , 2011, 197, W1060-W1066.	1.0	32
216	Is resection of colorectal liver metastases after a second-line chemotherapy regimen justified?. <i>Cancer</i> , 2011, 117, 4484-4492.	2.0	32

#	ARTICLE	IF	CITATIONS
217	Molecular Biomarkers for the Evaluation of Colorectal Cancer. American Journal of Clinical Pathology, 2017, 147, 221-260.	0.4	32
218	Proteomic Features of Colorectal Cancer Identify Tumor Subtypes Independent of Oncogenic Mutations and Independently Predict Relapse-Free Survival. Annals of Surgical Oncology, 2017, 24, 4051-4058.	0.7	32
219	Signet ring cell colorectal cancer: genomic insights into a rare subpopulation of colorectal adenocarcinoma. British Journal of Cancer, 2019, 121, 505-510.	2.9	32
220	BEACON CRC study safety lead-in (SLI) in patients with <i>BRAF</i> ^{V600E} metastatic colorectal cancer (mCRC): Efficacy and tumor markers.. Journal of Clinical Oncology, 2018, 36, 627-627.	0.8	32
221	BRAF inhibitors in clinical oncology. F1000prime Reports, 2013, 5, 11.	5.9	32
222	A New Surveillance Algorithm After Resection of Colorectal Liver Metastases Based on Changes in Recurrence Risk and RAS Mutation Status. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 1500-1508.	2.3	32
223	Combining Curcumin (Diferuloylmethane) and Heat Shock Protein Inhibition for Neurofibromatosis 2 Treatment: Analysis of Response and Resistance Pathways. Molecular Cancer Therapeutics, 2011, 10, 2094-2103.	1.9	31
224	BRAF-Directed Therapy in Metastatic Colorectal Cancer. Cancer Journal (Sudbury, Mass), 2016, 22, 175-178.	1.0	31
225	Nivolumab in the treatment of microsatellite instability high metastatic colorectal cancer. Future Oncology, 2018, 14, 1869-1874.	1.1	31
226	Comprehensive Clinical and Molecular Characterization of <i>KRAS</i> ^{G12C} -Mutant Colorectal Cancer. JCO Precision Oncology, 2021, 5, 613-621.	1.5	31
227	Circulating tumor DNA (ctDNA) utilizing a high-sensitivity panel to detect minimal residual disease post liver hepatectomy and predict disease recurrence.. Journal of Clinical Oncology, 2017, 35, 3522-3522.	0.8	31
228	Nivolumab (NIVO) + low-dose ipilimumab (IPI) in previously treated patients (pts) with microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Long-term follow-up.. Journal of Clinical Oncology, 2019, 37, 635-635.	0.8	31
229	Estimation of tumor cell total mRNA expression in 15 cancer types predicts disease progression. Nature Biotechnology, 2022, 40, 1624-1633.	9.4	31
230	RAS Mutation is Associated with Unsalvageable Recurrence Following Hepatectomy for Colorectal Cancer Liver Metastases. Annals of Surgical Oncology, 2018, 25, 2457-2466.	0.7	30
231	Genetic profiling as a clinical tool in advanced parathyroid carcinoma. Journal of Cancer Research and Clinical Oncology, 2019, 145, 1977-1986.	1.2	30
232	Contour prognostic model for predicting survival after resection of colorectal liver metastases: development and multicentre validation study using largest diameter and number of metastases with <i>RAS</i> mutation status. British Journal of Surgery, 2021, 108, 968-975.	0.1	30
233	ARID1A Mutation May Define an Immunologically Active Subgroup in Patients with Microsatellite Stable Colorectal Cancer. Clinical Cancer Research, 2021, 27, 1663-1670.	3.2	30
234	The requirement for freshly isolated human colorectal cancer (CRC) cells in isolating CRC stem cells. British Journal of Cancer, 2015, 112, 539-546.	2.9	29

#	ARTICLE	IF	CITATIONS
235	Molecular Biomarkers for the Evaluation of Colorectal Cancer: Guideline Summary From the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and American Society of Clinical Oncology. <i>Journal of Oncology Practice</i> , 2017, 13, 333-337.	2.5	29
236	First-in-human trial of the PI3K α -selective inhibitor SAR260301 in patients with advanced solid tumors. <i>Cancer</i> , 2018, 124, 315-324.	2.0	29
237	Detection of somatic mutations in cell-free DNA in plasma and correlation with overall survival in patients with solid tumors. <i>Oncotarget</i> , 2018, 9, 10259-10271.	0.8	29
238	Consensus statement on essential patient characteristics in systemic treatment trials for metastatic colorectal cancer: Supported by the ARCAD Group. <i>European Journal of Cancer</i> , 2018, 100, 35-45.	1.3	29
239	Circulating inflammation signature predicts overall survival and relapse-free survival in metastatic colorectal cancer. <i>British Journal of Cancer</i> , 2019, 120, 340-345.	2.9	29
240	International Harmonization of Provisional Diagnostic Criteria for <i>ERBB2</i> -Amplified Metastatic Colorectal Cancer Allowing for Screening by Next-Generation Sequencing Panel. <i>JCO Precision Oncology</i> , 2020, 4, 6-19.	1.5	29
241	Ongoing and future directions in the management of metastatic colorectal cancer: Update on clinical trials. <i>Journal of Surgical Oncology</i> , 2019, 119, 642-652.	0.8	28
242	Triple blockade of EGFR, MEK and PD-L1 has antitumor activity in colorectal cancer models with constitutive activation of MAPK signaling and PD-L1 overexpression. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 492.	3.5	28
243	Pilot Clinical Trial of Perioperative Durvalumab and Tremelimumab in the Treatment of Resectable Colorectal Cancer Liver Metastases. <i>Clinical Cancer Research</i> , 2021, 27, 3039-3049.	3.2	28
244	A retrospective study of ampullary adenocarcinomas: overall survival and responsiveness to fluoropyrimidine-based chemotherapy. <i>Annals of Oncology</i> , 2013, 24, 2349-2353.	0.6	27
245	APC and PIK3CA Mutational Cooperativity Predicts Pathologic Response and Survival in Patients Undergoing Resection for Colorectal Liver Metastases. <i>Annals of Surgery</i> , 2020, 272, 1080-1085.	2.1	27
246	Hurdles and Complexities of Codon 13 <i>KRAS</i> Mutations. <i>Journal of Clinical Oncology</i> , 2012, 30, 3565-3567.	0.8	26
247	Utility of a molecular prescreening program in advanced colorectal cancer for enrollment on biomarker-selected clinical trials. <i>Annals of Oncology</i> , 2016, 27, 1068-1074.	0.6	26
248	First-in-human trial of multikinase VEGF inhibitor regorafenib and anti-EGFR antibody cetuximab in advanced cancer patients. <i>JCI Insight</i> , 2017, 2, .	2.3	26
249	Current companion diagnostics in advanced colorectal cancer; getting a bigger and better piece of the pie. <i>Journal of Gastrointestinal Oncology</i> , 2017, 8, 199-212.	0.6	26
250	The Addition of Bevacizumab to Oxaliplatin-Based Chemotherapy: Impact Upon Hepatic Sinusoidal Injury and Thrombocytopenia. <i>Journal of the National Cancer Institute</i> , 2018, 110, 888-894.	3.0	26
251	Impact of RAS Mutations in Metastatic Colorectal Cancer After Potentially Curative Resection: Does Site of Metastases Matter?. <i>Annals of Surgical Oncology</i> , 2018, 25, 179-187.	0.7	26
252	Loss of muscle mass during preoperative chemotherapy as a prognosticator for poor survival in patients with colorectal liver metastases. <i>Surgery</i> , 2019, 165, 329-336.	1.0	26

#	ARTICLE	IF	CITATIONS
253	Population-based Screening for <i>BRAF</i> V600E in Metastatic Colorectal Cancer Reveals Increased Prevalence and Poor Prognosis. <i>Clinical Cancer Research</i> , 2020, 26, 4599-4605.	3.2	26
254	Modifying Practices in GI Oncology in the Face of COVID-19: Recommendations From Expert Oncologists on Minimizing Patient Risk. <i>JCO Oncology Practice</i> , 2020, 16, 383-388.	1.4	26
255	Combination of nivolumab (nivo) + ipilimumab (ipi) in the treatment of patients (pts) with deficient DNA mismatch repair (dMMR)/high microsatellite instability (MSI-H) metastatic colorectal cancer (mCRC): CheckMate 142 study.. <i>Journal of Clinical Oncology</i> , 2017, 35, 3531-3531.	0.8	26
256	Current and Future Approaches to Target the Epidermal Growth Factor Receptor and Its Downstream Signaling in Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2015, 14, 203-218.	1.0	25
257	Targeting <i>BRAF</i> -Mutant Colorectal Cancer: Progress in Combination Strategies. <i>Cancer Discovery</i> , 2017, 7, 558-560.	7.7	25
258	Clinical utility of circulating cell-free DNA in advanced colorectal cancer. <i>PLoS ONE</i> , 2017, 12, e0183949.	1.1	25
259	Platelet Metabolism and Other Targeted Drugs; Potential Impact on Immunotherapy. <i>Frontiers in Oncology</i> , 2018, 8, 107.	1.3	24
260	Individualized Treatment Sequencing Selection Contributes to Optimized Survival in Patients with Rectal Cancer and Synchronous Liver Metastases. <i>Annals of Surgical Oncology</i> , 2017, 24, 3857-3864.	0.7	23
261	Sequential Administration of XPO1 and ATR Inhibitors Enhances Therapeutic Response in TP53-mutated Colorectal Cancer. <i>Gastroenterology</i> , 2021, 161, 196-210.	0.6	23
262	Survival Benefit Associated With Surgical Oophorectomy in Patients With Colorectal Cancer Metastatic to the Ovary. <i>Clinical Colorectal Cancer</i> , 2012, 11, 191-194.	1.0	22
263	Joint prognostic effect of obesity and chronic systemic inflammation in patients with metastatic colorectal cancer. <i>Cancer</i> , 2015, 121, 2968-2975.	2.0	22
264	Study of Preanalytic and Analytic Variables for Clinical Next-Generation Sequencing of Circulating Cell-Free Nucleic Acid. <i>Journal of Molecular Diagnostics</i> , 2017, 19, 514-524.	1.2	22
265	Cancer <i>In Silico</i> Drug Discovery: A Systems Biology Tool for Identifying Candidate Drugs to Target Specific Molecular Tumor Subtypes. <i>Molecular Cancer Therapeutics</i> , 2014, 13, 3230-3240.	1.9	21
266	Preoperative Radiation Therapy With Concurrent Capecitabine, Bevacizumab, and Erlotinib for Rectal Cancer: A Phase I Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 88, 301-305.	0.4	21
267	Predictors of health-related quality of life and association with survival may identify colorectal cancer patients at high risk of poor prognosis. <i>Quality of Life Research</i> , 2017, 26, 319-330.	1.5	21
268	DNA Sequencing of Small Bowel Adenocarcinomas Identifies Targetable Recurrent Mutations in the ERBB2 Signaling Pathway. <i>Clinical Cancer Research</i> , 2019, 25, 641-651.	3.2	21
269	Development and Validation of a Gene Signature Classifier for Consensus Molecular Subtyping of Colorectal Carcinoma in a CLIA-Certified Setting. <i>Clinical Cancer Research</i> , 2021, 27, 120-130.	3.2	21
270	Real-World Study of Characteristics and Treatment Outcomes Among Patients with <i>KRAS</i> p.G12C-Mutated or Other <i>KRAS</i> Mutated Metastatic Colorectal Cancer. <i>Oncologist</i> , 2022, 27, 663-674.	1.9	21

#	ARTICLE	IF	CITATIONS
271	Oncologic and Functional Hazards of Obesity Among Patients With Locally Advanced Rectal Cancer Following Neoadjuvant Chemoradiation Therapy. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2017, 40, 277-282.	0.6	20
272	CTC analysis: an update on technological progress. <i>Translational Research</i> , 2019, 212, 14-25.	2.2	20
273	Global differences in the prevalence of the CpG island methylator phenotype of colorectal cancer. <i>BMC Cancer</i> , 2019, 19, 964.	1.1	20
274	Targeting ERBB2 (HER2) Amplification Identified by Next-Generation Sequencing in Patients With Advanced or Metastatic Solid Tumors Beyond Conventional Indications. <i>JCO Precision Oncology</i> , 2019, 3, 1-12.	1.5	20
275	Association of primary (1 st) site and molecular features with progression-free survival (PFS) and overall survival (OS) of metastatic colorectal cancer (mCRC) after anti-epidermal growth factor receptor (±EGFR) therapy. <i>Journal of Clinical Oncology</i> , 2016, 34, 3506-3506.	0.8	20
276	Comparison of Prognostic Genomic Predictors in Colorectal Cancer. <i>PLoS ONE</i> , 2013, 8, e60778.	1.1	20
277	Comparison of early radiological predictors of outcome in patients with colorectal cancer with unresectable hepatic metastases treated with bevacizumab. <i>Gut</i> , 2018, 67, 1095-1102.	6.1	19
278	BESPOKE study protocol: a multicentre, prospective observational study to evaluate the impact of circulating tumour DNA guided therapy on patients with colorectal cancer. <i>BMJ Open</i> , 2021, 11, e047831.	0.8	19
279	Implications of Intratumor Heterogeneity on Consensus Molecular Subtype (CMS) in Colorectal Cancer. <i>Cancers</i> , 2021, 13, 4923.	1.7	19
280	Cell membrane-anchored and tumor-targeted IL-12 (attIL12)-T cell therapy for eliminating large and heterogeneous solid tumors. , 2022, 10, e003633.		19
281	Embryonic origin of primary colon cancer predicts survival in patients undergoing ablation for colorectal liver metastases. <i>European Journal of Surgical Oncology</i> , 2017, 43, 1040-1049.	0.5	18
282	Preoperative radiation dose escalation for rectal cancer using a concomitant boost strategy improves tumor downstaging without increasing toxicity: A matched-pair analysis. <i>Advances in Radiation Oncology</i> , 2017, 2, 455-464.	0.6	18
283	Untying the gordian knot of targeting MET in cancer. <i>Cancer Treatment Reviews</i> , 2018, 66, 95-103.	3.4	18
284	Genomic Sequencing and Insight into Clinical Heterogeneity and Prognostic Pathway Genes in Patients with Metastatic Colorectal Cancer. <i>Journal of the American College of Surgeons</i> , 2021, 233, 272-284e13.	0.2	18
285	Adjuvant chemotherapy for stage II colon cancer. <i>Oncology</i> , 2008, 22, 260-70; discussion 270, 273, 275.	0.4	18
286	Metastasis of cancer: when and how?. <i>Annals of Oncology</i> , 2017, 28, 2045-2047.	0.6	17
287	Epidemiology and Molecular-Pathologic Characteristics of CpG Island Methylator Phenotype (CIMP) in Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2021, 20, 137-147.e1.	1.0	17
288	Alteration of FBXW7 is Associated with Worse Survival in Patients Undergoing Resection of Colorectal Liver Metastases. <i>Journal of Gastrointestinal Surgery</i> , 2021, 25, 186-194.	0.9	17

#	ARTICLE	IF	CITATIONS
289	Improved Survival over Time After Resection of Colorectal Liver Metastases and Clinical Impact of Multigene Alteration Testing in Patients with Metastatic Colorectal Cancer. <i>Journal of Gastrointestinal Surgery</i> , 2022, 26, 583-593.	0.9	17
290	Phase 1-2 trial of the BRAF inhibitor dabrafenib (D) plus MEK inhibitor trametinib (T) in BRAF V600 mutant colorectal cancer (CRC): Updated efficacy and biomarker analysis.. <i>Journal of Clinical Oncology</i> , 2014, 32, 3517-3517.	0.8	17
291	Pathological response following neoadjuvant immunotherapy in mismatch repair-deficient/microsatellite instability-high locally advanced, non-metastatic colorectal cancer. <i>British Journal of Surgery</i> , 2022, 109, 489-492.	0.1	17
292	Systematic Survey of Therapeutic Trials for Metastatic Colorectal Cancer: Room for Improvement in the Critical Pathway. <i>Journal of Clinical Oncology</i> , 2008, 26, 2000-2005.	0.8	16
293	A multicenter, multinational analysis of mitomycin C in refractory metastatic colorectal cancer. <i>European Journal of Cancer</i> , 2012, 48, 820-826.	1.3	16
294	Prognostic impact of perihepatic lymph node metastases in patients with resectable colorectal liver metastases. <i>British Journal of Surgery</i> , 2018, 105, 1200-1209.	0.1	16
295	AMPK β 1 confers survival advantage of colorectal cancer cells under metabolic stress by promoting redox balance through the regulation of glutathione reductase phosphorylation. <i>Oncogene</i> , 2020, 39, 637-650.	2.6	16
296	Sex Representation in Clinical Trials Associated with FDA Cancer Drug Approvals Differs Between Solid and Hematologic Malignancies. <i>Oncologist</i> , 2021, 26, 107-114.	1.9	16
297	Antitumor effects of cyclin dependent kinase 9 inhibition in esophageal adenocarcinoma. <i>Oncotarget</i> , 2017, 8, 28696-28710.	0.8	16
298	Hidden Biases in an Observational Study of Bevacizumab Beyond Progression. <i>Journal of Clinical Oncology</i> , 2009, 27, 1732-1733.	0.8	15
299	From multidisciplinary to personalized treatment of colorectal liver metastases: 4 reasons to consider RAS. <i>Cancer</i> , 2013, 119, 4083-4085.	2.0	15
300	Impact of Prior Hepatectomy History on Local Tumor Progression after Percutaneous Ablation of Colorectal Liver Metastases. <i>Journal of Vascular and Interventional Radiology</i> , 2018, 29, 395-403.e1.	0.2	15
301	Vestigial-like 1 is a shared targetable cancer-placenta antigen expressed by pancreatic and basal-like breast cancers. <i>Nature Communications</i> , 2020, 11, 5332.	5.8	15
302	Colon Cancer in Patients Under 25 Years Old: A Different Disease?. <i>Journal of the American College of Surgeons</i> , 2020, 230, 648-656.	0.2	15
303	BRAF V600 mutant colorectal cancer (CRC) expansion cohort from the phase I/II clinical trial of BRAF inhibitor dabrafenib (GSK2118436) plus MEK inhibitor trametinib (GSK1120212).. <i>Journal of Clinical Oncology</i> , 2012, 30, 3528-3528.	0.8	15
304	Phase 1B study of vemurafenib in combination with irinotecan and cetuximab in patients with BRAF-mutated advanced cancers and metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2014, 32, 3516-3516.	0.8	15
305	Identification of biomarkers of immune checkpoint blockade efficacy in recurrent or refractory solid tumor malignancies. <i>Oncotarget</i> , 2020, 11, 600-618.	0.8	15
306	Cytotoxic chemotherapy for advanced colorectal cancer. Recent advances in management. <i>Oncology</i> , 2005, 19, 11-7.	0.4	15

#	ARTICLE	IF	CITATIONS
307	Liquid biopsies for residual disease and recurrence. <i>Med</i> , 2021, 2, 1292-1313.	2.2	15
308	Management of adverse events from the treatment of encorafenib plus cetuximab for patients with BRAF V600E-mutant metastatic colorectal cancer: insights from the BEACON CRC study. <i>ESMO Open</i> , 2021, 6, 100328.	2.0	15
309	Src activity is modulated by oxaliplatin and correlates with outcomes after hepatectomy for metastatic colorectal cancer. <i>BMC Cancer</i> , 2014, 14, 660.	1.1	14
310	Nivolumab ± ipilimumab treatment (Tx) efficacy, safety, and biomarkers in patients (Pts) with metastatic colorectal cancer (mCRC) with and without high microsatellite instability (MSI-H): results from the CheckMate-142 study. <i>Annals of Oncology</i> , 2016, 27, vi158.	0.6	14
311	Planned Treatment of Advanced Metastatic Disease with Completion Ablation After Hepatic Resection. <i>Journal of Gastrointestinal Surgery</i> , 2017, 21, 628-635.	0.9	14
312	Bioactive lipid metabolism in platelet “first responder” and cancer biology. <i>Cancer and Metastasis Reviews</i> , 2018, 37, 439-454.	2.7	14
313	Identification of Actionable Fusions as an Anti-EGFR Resistance Mechanism Using a Circulating Tumor DNA Assay. <i>JCO Precision Oncology</i> , 2019, 3, 1-15.	1.5	14
314	Applying Precision to the Management of BRAF-Mutant Metastatic Colorectal Cancer. <i>Targeted Oncology</i> , 2020, 15, 567-577.	1.7	14
315	Clinical and Functional Characterization of Atypical KRAS/NRAS Mutations in Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 4587-4598.	3.2	14
316	Chromatin Remodeling of Colorectal Cancer Liver Metastasis is Mediated by an HGF/PU.1/DP4 Axis. <i>Advanced Science</i> , 2021, 8, e2004673.	5.6	14
317	Updated results of the BEACON CRC safety lead-in: Encorafenib (ENCO) + binimetinib (BINI) + cetuximab (CETUX) for BRAFV600E-mutant metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 688-688.	0.8	14
318	MIIP haploinsufficiency induces chromosomal instability and promotes tumour progression in colorectal cancer. <i>Journal of Pathology</i> , 2017, 241, 67-79.	2.1	13
319	M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF- β 2, in patients with heavily pretreated CRC: Preliminary results from a phase I trial.. <i>Journal of Clinical Oncology</i> , 2018, 36, 764-764.	0.8	13
320	Tumor Microenvironment in Gene Signatures: Critical Biology or Confounding Noise?. <i>Clinical Cancer Research</i> , 2016, 22, 3989-3991.	3.2	12
321	Integrated safety summary for trifluridine/tipiracil (TAS-102). <i>Anti-Cancer Drugs</i> , 2018, 29, 89-96.	0.7	12
322	Use of a Targeted Exome Next-Generation Sequencing Panel Offers Therapeutic Opportunity and Clinical Benefit in a Subset of Patients With Advanced Cancers. <i>JCO Precision Oncology</i> , 2019, 3, 1-14.	1.5	12
323	Atypical, Non-V600 BRAF Mutations as a Potential Mechanism of Resistance to EGFR Inhibition in Metastatic Colorectal Cancer. <i>JCO Precision Oncology</i> , 2019, 3, 1-10.	1.5	12
324	The BE GONE trial study protocol: a randomized crossover dietary intervention of dry beans targeting the gut microbiome of overweight and obese patients with a history of colorectal polyps or cancer. <i>BMC Cancer</i> , 2019, 19, 1233.	1.1	12

#	ARTICLE	IF	CITATIONS
325	Expanded Low Allele Frequency <i>RAS</i> and <i>BRAF</i> V600E Testing in Metastatic Colorectal Cancer as Predictive Biomarkers for Cetuximab in the Randomized CO.17 Trial. <i>Clinical Cancer Research</i> , 2021, 27, 52-59.	3.2	12
326	SO-27 Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142. <i>Annals of Oncology</i> , 2021, 32, S213-S214.	0.6	12
327	A feasibility study of returning clinically actionable somatic genomic alterations identified in a research laboratory. <i>Oncotarget</i> , 2017, 8, 41806-41814.	0.8	12
328	The establishment of a palliative care consult team in a comprehensive cancer center. <i>Journal of Clinical Oncology</i> , 2005, 23, 8093-8093.	0.8	12
329	Targeting SRC and epidermal growth factor receptor in colorectal cancer: rationale and progress into the clinic. <i>Gastrointestinal Cancer Research: GCR</i> , 2007, 1, S37-41.	0.8	12
330	Convergence of Nanotechnology and Cancer Prevention: Are We There Yet?. <i>Cancer Prevention Research</i> , 2014, 7, 973-992.	0.7	11
331	Evaluating for Pseudoprogression in Colorectal and Pancreatic Tumors Treated With Immunotherapy. <i>Journal of Immunotherapy</i> , 2018, 41, 284-291.	1.2	11
332	Targeting CDK9 and MCL-1 by a new CDK9/p-TEFb inhibitor with and without 5-fluorouracil in esophageal adenocarcinoma. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591986485.	1.4	11
333	A novel patient-derived orthotopic xenograft model of esophageal adenocarcinoma provides a platform for translational discoveries. <i>DMM Disease Models and Mechanisms</i> , 2019, 12, .	1.2	11
334	Mutation and copy number discordance in primary versus metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2014, 32, 3509-3509.	0.8	11
335	Emerging drugs for colorectal cancer. <i>Expert Opinion on Emerging Drugs</i> , 2008, 13, 629-642.	1.0	10
336	Sequenced Chemotherapy and Surgery for Potentially Resectable Colorectal Liver Metastases: A Debate Over Goals of Research and an Approach While the Jury Remains Out. <i>Annals of Surgical Oncology</i> , 2010, 17, 1983-1986.	0.7	10
337	Overcoming Resistance to MAPK Pathway Inhibitors. <i>Journal of the National Cancer Institute</i> , 2013, 105, 9-10.	3.0	10
338	Prognostic factors after resection of colorectal liver metastases following preoperative second-line chemotherapy: Impact of RAS mutations. <i>European Journal of Surgical Oncology</i> , 2016, 42, 1378-1384.	0.5	10
339	Phase I studies of vorinostat with ixazomib or pazopanib imply a role of antiangiogenesis-based therapy for TP53 mutant malignancies. <i>Scientific Reports</i> , 2020, 10, 3080.	1.6	10
340	The Provocative Roles of Platelets in Liver Disease and Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 643815.	1.3	10
341	Phase Ib study of vemurafenib in combination with irinotecan and cetuximab in patients with BRAF-mutated metastatic colorectal cancer and advanced cancers.. <i>Journal of Clinical Oncology</i> , 2015, 33, 3511-3511.	0.8	10
342	A phase II and co-clinical study of an AKT inhibitor in patients (pts) with biomarker-enriched, previously treated metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 3563-3563.	0.8	10

#	ARTICLE	IF	CITATIONS
343	Genomic analysis of exceptional responder to regorafenib in treatment-refractory metastatic rectal cancer: a case report and review of the literature. <i>Oncotarget</i> , 2017, 8, 57882-57888.	0.8	10
344	PI-3-Kinase Inhibitors in Colorectal Cancer. <i>Current Cancer Drug Targets</i> , 2011, 11, 190-198.	0.8	10
345	The Future of ctDNA-Defined Minimal Residual Disease: Personalizing Adjuvant Therapy in Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2022, 21, 89-95.	1.0	10
346	Overall Survival in Phase 3 Clinical Trials and the Surveillance, Epidemiology, and End Results Database in Patients With Metastatic Colorectal Cancer, 1986-2016. <i>JAMA Network Open</i> , 2022, 5, e2213588.	2.8	10
347	BEACON CRC study safety lead-in: Assessment of the BRAF inhibitor encorafenib + MEK inhibitor binimetinib + anti-epidermal growth factor receptor antibody cetuximab for BRAFV600E metastatic colorectal cancer. <i>Annals of Oncology</i> , 2018, 29, v109.	0.6	9
348	Expanded Analysis of Secondary Germline Findings From Matched Tumor/Normal Sequencing Identifies Additional Clinically Significant Mutations. <i>JCO Precision Oncology</i> , 2019, 3, 1-11.	1.5	9
349	Sulindac plus a phospholipid is effective for polyp reduction and safer than sulindac alone in a mouse model of colorectal cancer development. <i>BMC Cancer</i> , 2020, 20, 871.	1.1	9
350	Medical Oncologists' Perspectives on How the Results of the IDEA Collaboration Impact the Adjuvant Treatment of Stage III Colon Cancer. <i>Oncologist</i> , 2020, 25, 229-234.	1.9	9
351	P-71 KRYSTAL-10: A randomized phase 3 study of adagrasib (MRTX849) in combination with cetuximab vs chemotherapy in patients with previously treated advanced colorectal cancer with KRASG12C mutation. <i>Annals of Oncology</i> , 2021, 32, S121.	0.6	9
352	Preliminary results from a phase II study of infusional 5-FU, leucovorin, and irinotecan (FOLFIRI) plus bevacizumab as first-line treatment for metastatic colorectal cancer (mCRC). <i>Journal of Clinical Oncology</i> , 2006, 24, 3579-3579.	0.8	9
353	Circulating tumor DNA (ctDNA) as an early marker to monitor clinical benefit of regorafenib and TAS-102 in patients with metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 3533-3533.	0.8	9
354	Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) study (NRG-GI004/SWOG-S1610): A randomized phase III study of mFOLFOX6/bevacizumab combination chemotherapy with or without atezolizumab or atezolizumab monotherapy in the first-line treatment of patients with deficient DNA mismatch repair (dMMR) metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS3615-TPS3615.	0.8	9
355	Quality of life with encorafenib plus cetuximab with or without binimetinib treatment in patients with BRAF V600E-mutant metastatic colorectal cancer: patient-reported outcomes from BEACON CRC. <i>ESMO Open</i> , 2022, 7, 100477.	2.0	9
356	Barriers to Integrating Gene Profiling for Stage II Colon Cancer. <i>Clinical Cancer Research</i> , 2009, 15, 7451-7452.	3.2	8
357	Real-Time Interrogation of Aspirin Reactivity, Biochemistry, and Biodistribution by Hyperpolarized Magnetic Resonance Spectroscopy. <i>Angewandte Chemie - International Edition</i> , 2019, 58, 4179-4183.	7.2	8
358	Going with the Flow: The Promise of Plasma-Only Circulating Tumor DNA Assays. <i>Clinical Cancer Research</i> , 2021, 27, 5449-5451.	3.2	8
359	Pharmacodynamic and efficacy analysis of the BRAF inhibitor dabrafenib (GSK436) in combination with the MEK inhibitor trametinib (GSK212) in patients with BRAFV600 mutant colorectal cancer (CRC).. <i>Journal of Clinical Oncology</i> , 2013, 31, 3507-3507.	0.8	8
360	Not all RAS mutations created equal: Functional and clinical characterization of 80 different KRAS and NRAS mutations.. <i>Journal of Clinical Oncology</i> , 2017, 35, 3589-3589.	0.8	8

#	ARTICLE	IF	CITATIONS
361	Anti-EGFR resistant clones decay exponentially after progression: Implications for anti-EGFR rechallenge.. Journal of Clinical Oncology, 2018, 36, 3511-3511.	0.8	8
362	A randomized phase II study of trastuzumab and pertuzumab (TP) compared to cetuximab and irinotecan (CETIRI) in advanced/metastatic colorectal cancer (mCRC) with HER2 amplification: S1613.. Journal of Clinical Oncology, 2018, 36, TPS3620-TPS3620.	0.8	8
363	Association of PIK3CA mutations (mut) with immune engagement and clinical benefit from immunotherapy in microsatellite stable (MSS) colorectal cancer (CRC) patients (pts).. Journal of Clinical Oncology, 2019, 37, 3604-3604.	0.8	8
364	Therapeutic vulnerabilities among KRAS G12C mutant (mut) advanced cancers based on co-alteration (co-alt) patterns.. Journal of Clinical Oncology, 2020, 38, 3625-3625.	0.8	8
365	Efficiency of biomarker screening for enriched metastatic colorectal cancer trials: The ATTACC program experience.. Journal of Clinical Oncology, 2014, 32, 3619-3619.	0.8	8
366	Efficacy and Safety of Cetuximab Dosing (biweekly vs weekly) in Patients with <i>KRAS</i> Wild-type Metastatic Colorectal Cancer: A Meta-analysis. Oncologist, 2022, 27, 371-379.	1.9	8
367	Pulmonary arteriovenous fistula in a patient with renal cell carcinoma. European Respiratory Journal, 2007, 29, 813-815.	3.1	7
368	Early-Onset Signet-Ring Cell Adenocarcinoma of the Colon: A Case Report and Review of the Literature. Case Reports in Oncological Medicine, 2017, 2017, 1-7.	0.2	7
369	Non-invasive genotyping of metastatic colorectal cancer using circulating cell free DNA. Cancer Genetics, 2019, 237, 82-89.	0.2	7
370	Liquid biopsy, a paradigm shift in oncology: what interventional radiologists should know. European Radiology, 2020, 30, 4496-4503.	2.3	7
371	Phase II trial of bintrafusp alfa in patients with metastatic MSI-H cancers following progression on immunotherapy.. Journal of Clinical Oncology, 2021, 39, 79-79.	0.8	7
372	Abstract 2603: Exploratory analysis of Janus kinase 1 (JAK1) loss-of-function (LoF) mutations in patients with DNA mismatch repair-deficient/microsatellite instability-high (dMMR/MSI-H) metastatic colorectal cancer (mCRC) treated with nivolumab + ipilimumab in CheckMate-142. Cancer Research, 2018, 78, 2603-2603.	0.4	7
373	Distinct impacts of KRAS, NRAS and BRAF mutations on survival of patients with metastatic colorectal cancer.. Journal of Clinical Oncology, 2018, 36, 3513-3513.	0.8	7
374	Activity of EGFR inhibition in atypical (non-V600E) BRAF-mutated metastatic colorectal cancer.. Journal of Clinical Oncology, 2019, 37, 596-596.	0.8	7
375	RETRIEVAL OF AEROSOL OPTICAL THICKNESS BY MEANS OF THE LEAST-MEDIAN-SQUARES ROBUST ALGORITHM. Journal of Aerosol Science, 1999, 30, 805-817.	1.8	6
376	Second-Line Chemotherapy Use in Metastatic Colon Cancer Varies by Disease Responsiveness. Clinical Colorectal Cancer, 2008, 7, 55-59.	1.0	6
377	Outcomes in 144 Patients With Colorectal Cancer Treated in a Phase I Clinic: The MD Anderson Cancer Center Experience. Clinical Colorectal Cancer, 2012, 11, 297-303.	1.0	6
378	Residual tumor thickness at the tumor-normal tissue interface predicts the recurrence-free survival in patients with liver metastasis of breast cancer. Annals of Diagnostic Pathology, 2014, 18, 266-270.	0.6	6

#	ARTICLE	IF	CITATIONS
379	Why a One Size Fits All Approach to <i>RAS</i> Might Not Fit Colorectal Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2017, 15, 545-547.	2.3	6
380	“Right Drug for the Right Patient” Hurdles and the Path Forward in Colorectal Cancer. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2013, 33, e115-e120.	1.8	6
381	Phase II study of infusional 5-fluorouracil, leucovorin, and irinotecan (FOLFIRI) plus bevacizumab as first-line treatment for metastatic colorectal cancer. Journal of Clinical Oncology, 2007, 25, 4089-4089.	0.8	6
382	Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) study (NRG-GI004/SWOG-S1610): A randomized phase III study of mFOLFOX6/bevacizumab combination chemotherapy with or without atezolizumab or atezolizumab monotherapy in the first-line treatment of patients (pts) with deficient DNA mismatch repair (dMMR) metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 2019, 37, TPS728-TPS728.	0.8	6
383	Targeting cyclin-dependent kinase 9 by a novel inhibitor enhances radiosensitization and identifies Axl as a novel downstream target in esophageal adenocarcinoma. Oncotarget, 2019, 10, 4703-4718.	0.8	6
384	Of vascular defense, hemostasis, cancer, and platelet biology: an evolutionary perspective. Cancer and Metastasis Reviews, 2022, 41, 147-172.	2.7	6
385	KRAS mutation in colorectal cancer metastases after adjuvant FOLFOX for the primary. British Journal of Cancer, 2012, 107, 1442-1443.	2.9	5
386	Platelets: “First Responders” in Cancer Progression and Metastasis. , 2017, , 1111-1132.		5
387	Refining the Use of Adjuvant Oxaliplatin in Clinical Stage II or III Rectal Adenocarcinoma. Oncologist, 2019, 24, e671-e676.	1.9	5
388	PULSE: A randomized phase II open label study of panitumumab rechallenge versus standard therapy after progression on anti-EGFR therapy in patients with <i>RAS</i> wild-type metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 2021, 39, TPS143-TPS143.	0.8	5
389	Methylation-eQTL analysis in cancer research. Bioinformatics, 2021, 37, 4014-4022.	1.8	5
390	First-in-human phase I trial of the PI3Kb-selective inhibitor SAR260301 in patients with advanced solid tumors (NCT01673737).. Journal of Clinical Oncology, 2015, 33, 2564-2564.	0.8	5
391	Is the neutrophil-lymphocyte ratio (NLR) a predictive and prognostic factor in rectal cancer patients treated with neoadjuvant chemoradiation (nCRT)?.. Journal of Clinical Oncology, 2016, 34, 3605-3605.	0.8	5
392	Concordance of DNA mismatch repair deficient (dMMR)/microsatellite instability (MSI) assessment by local and central testing in patients with metastatic CRC (mCRC) receiving nivolumab (nivo) in CheckMate 142 study.. Journal of Clinical Oncology, 2017, 35, 3548-3548.	0.8	5
393	International harmonization of diagnostic criteria for HER2-amplified metastatic colorectal cancer and application of targeted next-generation sequencing panel as a diagnostic method.. Journal of Clinical Oncology, 2018, 36, 3594-3594.	0.8	5
394	“Right Drug for the Right Patient” Hurdles and the Path Forward in Colorectal Cancer. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2013, , e115-e120.	1.8	5
395	Proteomic features of colorectal cancer independently predict relapse-free survival.. Journal of Clinical Oncology, 2015, 33, 616-616.	0.8	5
396	Systemic cytotoxic and biologic therapies for colorectal cancer liver metastases: expert consensus statement. Hpb, 2013, 15, 116-118.	0.1	4

#	ARTICLE	IF	CITATIONS
397	Development and Application of Duplex Sequencing Strategy for Cell-Free DNA-Based Longitudinal Monitoring of Stage IV Colorectal Cancer. <i>Journal of Molecular Diagnostics</i> , 2019, 21, 994-1009.	1.2	4
398	The use of 5-fluorouracil and oxaliplatin (FOLFOX) for colorectal cancer is associated with the development of splenomegaly and thrombocytopenia. <i>Journal of Clinical Oncology</i> , 2008, 26, 4102-4102.	0.8	4
399	Prevalence of incidental actionable germline mutations in 1,000 advanced cancer patients on a prospective somatic genomic profiling program.. <i>Journal of Clinical Oncology</i> , 2015, 33, 1510-1510.	0.8	4
400	LUNA: A randomized phase II trial of liver resection plus chemotherapy or chemotherapy alone in patients with unresectable lung and resectable liver metastases from colorectal adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS3625-TPS3625.	0.8	4
401	Actionable fusions in colorectal cancer using a cell-free circulating tumor DNA (ctDNA) assay.. <i>Journal of Clinical Oncology</i> , 2018, 36, 3507-3507.	0.8	4
402	The characteristics of ARID1A mutations in colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, 3595-3595.	0.8	4
403	An analysis of research biopsy core variability from over 5000 prospectively collected core samples. <i>Npj Precision Oncology</i> , 2021, 5, 94.	2.3	4
404	Rechallenge with anti-EGFR-based therapy in metastatic colorectal cancer: Impact of intervening time interval and prior anti-EGFR response.. <i>Journal of Clinical Oncology</i> , 2014, 32, 3607-3607.	0.8	4
405	Identification of Gene Co-Expression Networks Associated with Consensus Molecular Subtype-1 of Colorectal Cancer. <i>Cancers</i> , 2021, 13, 5824.	1.7	4
406	Don't blame the messenger: lessons learned for cancer mRNA vaccines during the COVID-19 pandemic. <i>Nature Reviews Cancer</i> , 2022, 22, 317-318.	12.8	4
407	Coordination of care in colon cancer. <i>Cancer</i> , 2015, 121, 3201-3202.	2.0	3
408	Accelerating Therapeutic Development through Innovative Trial Design in Colorectal Cancer. <i>Current Treatment Options in Oncology</i> , 2018, 19, 11.	1.3	3
409	Population pharmacokinetics and covariate analysis of Sym004, an antibody mixture against the epidermal growth factor receptor, in subjects with metastatic colorectal cancer and other solid tumors. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2020, 47, 5-18.	0.8	3
410	FOLFOXIRI Versus Doublet Regimens in Right-Sided Metastatic Colorectal Cancer: Focus on Subsequent Therapies and Impact on Overall Survival. <i>Clinical Colorectal Cancer</i> , 2020, 19, 248-255.e6.	1.0	3
411	Utility of circulating tumor DNA in the clinical management of patients with BRAF ^{V600E} metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2021, 39, 119-119.	0.8	3
412	SO-11 KISIMA-01 trial: Safety, tolerability and immunogenicity of ATP128 with or without ezabenlimab (BI) Tj ETQq0 0 0 rgBT /Overlock of Oncology, 2021, 32, S206-S207.	0.6	3
413	Are Homologous Recombination Deficiency Mutations Relevant in Colorectal Cancer?. <i>Journal of the National Cancer Institute</i> , 2022, 114, 176-178.	3.0	3
414	Heterogeneity of acquired KRAS and EGFR mutations in colorectal cancer patients treated with anti-EGFR monoclonal antibodies.. <i>Journal of Clinical Oncology</i> , 2013, 31, 3512-3512.	0.8	3

#	ARTICLE	IF	CITATIONS
415	Prognostic implications of TAMs in colorectal cancer hepatic metastases.. Journal of Clinical Oncology, 2017, 35, 3574-3574.	0.8	3
416	BEACON CRC (binimetinib [BINI], encorafenib [ENCO], and cetuximab [CTX] combined to treat) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 7 phase III study of ENCO plus CTX plus or minus BINI vs irinotecan (IRI)/CTX or infusional 5-fluorouracil/folinic acid/IRI (FOLFIRI)/CTX with a safety lead-in of ENCO + BINI + CTX in patients (Pts) with BRAFV600E mCRC.. Journal of Clinical Oncology, 2017, 35, TPS3622-TPS3622.	0.8	3
417	Association of phosphatidylinositol 3-kinase (PI3K) pathway activation with increased immune checkpoint expression in colorectal cancer (CRC) patients.. Journal of Clinical Oncology, 2018, 36, 653-653.	0.8	3
418	Detection and description of ERBB2 amplification using circulating cell free tumor DNA (ctDNA) genomic analysis in metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 2018, 36, 661-661.	0.8	3
419	Platelet microparticles: small payloads with profound effects on tumor growth. Non-coding RNA Investigation, 2017, 1, 15-15.	0.6	3
420	Phase 1b/2 study of binimetinib (BINI) in combination with nivolumab (NIVO) or NIVO plus ipilimumab (IPI) in patients (pts) with previously treated microsatellite-stable (MSS) metastatic colorectal cancer (mCRC) with RAS mutation.. Journal of Clinical Oncology, 2018, 36, TPS870-TPS870.	0.8	3
421	A priori filtering of post-operative (post-op) circulating tumor DNA (ctDNA) to predict recurrence in post-metastasectomy colorectal cancer patients (CRC pts) without knowledge of tumor genotype.. Journal of Clinical Oncology, 2018, 36, 12044-12044.	0.8	3
422	Population-based screening for <i>BRAF</i> V600E in metastatic colorectal cancer (mCRC) to reveal true prognosis.. Journal of Clinical Oncology, 2019, 37, 3579-3579.	0.8	3
423	A systematic review of surrogate endpoints (SEPs) for overall survival (OS) in metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 2019, 37, e18206-e18206.	0.8	3
424	Combined MEK/MDM2 inhibition demonstrates antitumor efficacy in TP53 wild-type thyroid and colorectal cancers with MAPK alterations. Scientific Reports, 2022, 12, 1248.	1.6	3
425	NRG-G1004/SWOG-S1610: Colorectal cancer metastatic dMMR immuno-therapy (COMMIT) study. A randomized phase III study of atezolizumab (atezo) monotherapy versus mFOLFOX6/bevacizumab/atezo in the first-line treatment of patients (pts) with deficient DNA mismatch repair (dMMR) or microsatellite instability high (MSI-H) metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 2022, 40, TPS232-TPS232.	0.8	3
426	A phase II study of UFT with leucovorin administered as a twice daily schedule in the treatment of patients with metastatic colorectal cancer. British Journal of Cancer, 2008, 99, 722-726.	2.9	2
427	Commentary: Practice Patterns and Potential Impact on Quality Measures for a Practicing Physician. Journal of Oncology Practice, 2009, 5, 233-235.	2.5	2
428	1 Feasibility of large-scale genomic testing to facilitate enrollment on genomically-matched clinical trials. European Journal of Cancer, 2014, 50, 3.	1.3	2
429	Distinct Patient and Tumor Characteristics of the Consensus Molecular Subtypes of Colorectal Cancer. Gastroenterology, 2017, 152, S880.	0.6	2
430	Can Circulating Tumor DNA in Early-Stage Colorectal Cancer Be More Than a Prognostic Biomarker?. JAMA Oncology, 2019, 5, 1101.	3.4	2
431	Patient-reported Symptom Outcomes and Microsatellite Instability in Patients With Metastatic Colorectal Cancer. Clinical Colorectal Cancer, 2020, 19, 48-56.e2.	1.0	2
432	45P A meta-analysis of efficacy and safety of cetuximab with biweekly vs. weekly dosing. Annals of Oncology, 2020, 31, S435.	0.6	2

#	ARTICLE	IF	CITATIONS
433	LBA-7 Encorafenib plus cetuximab with or without binimetinib for BRAFV600E metastatic colorectal cancer (mCRC): Relationship between carcinoembryonic antigen (CEA) and clinical outcomes from BEACON CRC. <i>Annals of Oncology</i> , 2020, 31, S243.	0.6	2
434	Phase II/III study of circulating tumor DNA as a predictive biomarker in adjuvant chemotherapy in patients with stage II colon cancer:NRG-GI005 (COBRA).. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS148-TPS148.	0.8	2
435	NRG-GI004/SWOG-S1610: Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study: A randomized phase III study of atezolizumab (atezo) monotherapy versus mFOLFOX6/bevacizumab/atezo in the first-line treatment of patients (pts) with deficient DNA mismatch repair (dMMR) or microsatellite instability high (MSI-H) metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS150-TPS150.	0.8	2
436	An open-label, phase II study of patritumab deruxtecan (HER3-DXd, U3-1402) in patients (pts) with previously treated advanced/metastatic colorectal cancer (CRC).. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS157-TPS157.	0.8	2
437	SO-28 Effect of prior bevacizumab treatment in BRAF V600E-mutant metastatic colorectal cancer: Overall survival with encorafenib + cetuximab +/- binimetinib in BEACON CRC. <i>Annals of Oncology</i> , 2021, 32, S214.	0.6	2
438	Characteristics and outcomes of dementia residents in an assisted living facility. <i>International Journal of Geriatric Psychiatry</i> , 2000, 15, 586-593.	1.3	2
439	Targeted Therapy in Colorectal Cancer. , 2008, , 101-123.		2
440	Abstract 8: Global and targeted metabolomic profiling of colorectal cancer progression. , 2016, , .		2
441	Differences in sites of metastatic disease and outcomes observed in patients with BRAF mutant colorectal cancers.. <i>Journal of Clinical Oncology</i> , 2010, 28, 3592-3592.	0.8	2
442	Exploratory analysis of adjuvant chemotherapy effects after preoperative chemoradiotherapy and radical resection for rectal cancer.. <i>Journal of Clinical Oncology</i> , 2012, 30, 557-557.	0.8	2
443	Genomic classifier (ColoPrint) to predict outcome and chemotherapy benefit in stage II and III colon cancer patients.. <i>Journal of Clinical Oncology</i> , 2013, 31, 3612-3612.	0.8	2
444	Genomic classifiers (ColoPrint/MSI-Print) predict outcome and chemotherapy benefit in stage II and III colon cancer patients.. <i>Journal of Clinical Oncology</i> , 2013, 31, 378-378.	0.8	2
445	Frequency of concurrent gene mutations and copy number alterations in circulating cell-free DNA (cfDNA) from refractory metastatic CRC patients.. <i>Journal of Clinical Oncology</i> , 2014, 32, 11117-11117.	0.8	2
446	Associations between patient (pt) colorectal cancer (CRC) tumor KRAS and BRAF mutation (mut) status and overall survival (OS).. <i>Journal of Clinical Oncology</i> , 2014, 32, 473-473.	0.8	2
447	Prospective evaluation of a 409-gene next generation sequencing platform to facilitate genotype-matched clinical trial enrollment.. <i>Journal of Clinical Oncology</i> , 2015, 33, 3608-3608.	0.8	2
448	S1406: Randomized phase II study of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2015, 33, TPS790-TPS790.	0.8	2
449	Immunologic profiling of consensus molecular subtype (CMS) stratified colorectal cancer (CRC) primary and liver metastectomy specimens: Implications for immune targeting of proficient mismatch repair CRC.. <i>Journal of Clinical Oncology</i> , 2016, 34, 3520-3520.	0.8	2
450	Impact of microsatellite instability (MSI) on tumor clonal evolution in metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 616-616.	0.8	2

#	ARTICLE	IF	CITATIONS
451	Serial monitoring of ctDNA to highlight mutation profiles in colorectal cancer.. Journal of Clinical Oncology, 2018, 36, 641-641.	0.8	2
452	Expanded RAS and BRAF V600 testing as predictive biomarkers for single agent cetuximab in the randomized phase III CO.17 trial.. Journal of Clinical Oncology, 2019, 37, 537-537.	0.8	2
453	Retrospective evaluation of patients with colorectal cancer (CRC) and type II non-insulin-dependent diabetes (NIDDM).. Journal of Clinical Oncology, 2011, 29, 507-507.	0.8	2
454	Survival advantage associated with metformin usage in patients with colorectal cancer (CRC) and type II noninsulin-dependent diabetes (NIDDM).. Journal of Clinical Oncology, 2011, 29, 3618-3618.	0.8	2
455	Use of bevacizumab to reduce the rate of oxaliplatin-induced thrombocytopenia and splenomegaly.. Journal of Clinical Oncology, 2012, 30, 564-564.	0.8	2
456	Abstract LB-235: COLOMATE: Colorectal cancer and liquid biopsy screening protocol for molecularly assigned therapy. Cancer Research, 2019, 79, LB-235-LB-235.	0.4	2
457	A Bayesian phase I/II platform design for coâ€developing drug combination therapies for multiple indications. Statistics in Medicine, 2022, 41, 374-389.	0.8	2
458	Novel Therapies in Development for Metastatic Colorectal Cancer. Gastrointestinal Cancer Research: GCR, 2014, 7, S2-7.	0.8	2
459	Arginine methylation of EGFR: a new biomarker for predicting resistance to anti-EGFR treatment. American Journal of Cancer Research, 2017, 7, 2587-2599.	1.4	2
460	The immune impact of PI3K-AKT pathway inhibition in colorectal cancer.. Journal of Clinical Oncology, 2022, 40, 154-154.	0.8	2
461	Clinical and pathologic features correlated with rare favorable survival in patients with BRAFV600E mutated colorectal cancer. Journal of Gastrointestinal Oncology, 2022, 13, 647-656.	0.6	2
462	The emergence of targetable pathways in colorectal cancer.. Clinical Advances in Hematology and Oncology, 2021, 19, 774-783.	0.3	2
463	Reply to D.J. Gallagher et al. Journal of Clinical Oncology, 2009, 27, e20-e21.	0.8	1
464	Challenges and strategies for identifying biomarkers for colorectal cancer. Colorectal Cancer, 2013, 2, 487-489.	0.8	1
465	Efficacy and safety of Sym004 in refractory metastatic colorectal cancer with acquired resistance to anti-EGFR therapy: Results of a randomized phase II study (RP2S). Annals of Oncology, 2017, 28, v160.	0.6	1
466	Phase II study of DFP-10917, a deoxycytidine analog, given by 14-day continuous intravenous infusion for chemotherapy-refractory advanced colorectal cancer. Investigational New Drugs, 2018, 36, 895-902.	1.2	1
467	Two phase I, pharmacokinetic, and pharmacodynamic studies of DFP-10917, a novel nucleoside analog with 14-day and 7-day continuous infusion schedules. Investigational New Drugs, 2019, 37, 76-86.	1.2	1
468	Reply to S. Boutayeb et al. JCO Oncology Practice, 2020, 16, 525-525.	1.4	1

#	ARTICLE	IF	CITATIONS
469	85MO Management of adverse events associated with encorafenib plus cetuximab in patients with BRAF V600E mutant metastatic colorectal cancer (BEACON CRC Study). <i>Annals of Oncology</i> , 2020, 31, S1276.	0.6	1
470	Integration of Whole-Genome Sequencing With Circulating Tumor DNA Analysis Captures Clonal Evolution and Tumor Heterogeneity in Non-V600 BRAF Mutant Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2020, 19, 132-136.e3.	1.0	1
471	Global BRAF testing practices in metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2021, 39, 128-128.	0.8	1
472	Real-world genomic and treatment landscape in advanced colorectal cancer identifies treatment differences pre- and post-ctDNA genomic profiling.. <i>Journal of Clinical Oncology</i> , 2021, 39, 39-39.	0.8	1
473	Phase II/III study of Circulating tumor DNA as a predictive Biomarker in Adjuvant chemotherapy in patients with stage II colon cancer: NRG-GI005 (COBRA).. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS3622-TPS3622.	0.8	1
474	Serial circulating tumor DNA (ctDNA) monitoring in metastatic colorectal cancer (mCRC) reveals dynamic profile of actionable alterations.. <i>Journal of Clinical Oncology</i> , 2021, 39, 3572-3572.	0.8	1
475	Abstract A012: Humanized patient-derived xenografts (PDXs) recapitulate clinical responses in microsatellite stable (MSS) and unstable (MSI-H) colorectal cancer (CRC). , 2018, , .		1
476	Abstract LB-228: Resistance to BRAF inhibition in BRAF V600E colorectal cancer is associated with PI3K/AKT activation and hypermethylation. <i>Cancer Research</i> , 2011, 71, LB-228-LB-228.	0.4	1
477	Abstract 35: A universal marker for the detection of epithelial-mesenchymal transitioned circulating tumor cells and their prognostic relevance in epithelial cancers. , 2014, , .		1
478	Abstract 5371: Drug repositioning with a bioinformatics platform that integrates the TCGA, cMap and CCLE. , 2014, , .		1
479	Abstract 1596: Detection of PD-L1 in cell surface vimentin positive circulating tumor cells is associated with poor survival in cancer patients. , 2015, , .		1
480	Abstract 1662: Development and validation of humanized mice models implanted with patient derived colorectal cancer xenografts. , 2017, , .		1
481	Abstract 414: Identifying selective vulnerabilities in colorectal cancer molecular subtypes using in vivo functional genomic screens. , 2017, , .		1
482	Abstract 3859: Targeting CDK9 and MCL-1 by a New CDK9/p-TEFB Inhibitor with and without 5-fluorouracil in esophageal adenocarcinoma. , 2019, , .		1
483	Presence of survivin-specific cytotoxic T-lymphocytes (CTLs) in pancreatic cancer patients, and specific killing of human pancreatic carcinoma cells in vitro by survivin-specific CTLs. <i>Journal of Clinical Oncology</i> , 2007, 25, 3070-3070.	0.8	1
484	Two phase I, pharmacokinetic (PK) and pharmacodynamic (PD) studies of TAS-109, a novel nucleoside analogue with 14 days and 7 days continuous infusion (CI) schedules. <i>Journal of Clinical Oncology</i> , 2008, 26, 2577-2577.	0.8	1
485	MET overexpression as a hallmark of the epithelial-mesenchymal transition (EMT) phenotype in colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2013, 31, 334-334.	0.8	1
486	Increased gene copy number and amplification of FGF2 and FGFR1 in metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2013, 31, 402-402.	0.8	1

#	ARTICLE	IF	CITATIONS
487	Impact of PI3K aberrations on efficacy of perifosine (P), x-PECT: A phase III randomized study of P plus capecitabine (PC) versus placebo plus capecitabine (C) in refractory metastatic colorectal cancer (mCRC) patients.. Journal of Clinical Oncology, 2014, 32, 3606-3606.	0.8	1
488	A phase I/II study of azacitidine and capecitabine/oxaliplatin (CAPOX) in refractory CIMP-high metastatic colorectal cancer.. Journal of Clinical Oncology, 2014, 32, 488-488.	0.8	1
489	Antibody-independent isolation and characterization of circulating tumor cells using dielectrophoresis: Fluid flow fractionation in metastatic colorectal cancer.. Journal of Clinical Oncology, 2016, 34, e23023-e23023.	0.8	1
490	Role of MEK inhibition in improving anti-tumor responses in xenograft models of BRAF-mutated metastatic colorectal cancer.. Journal of Clinical Oncology, 2016, 34, 265-265.	0.8	1
491	Prevalence of incidental germline pathogenic (PV) and likely pathogenic (LPV) variants in hereditary cancer-related genes identified in matched tumor/normal sequencing of advanced solid tumors.. Journal of Clinical Oncology, 2017, 35, 1524-1524.	0.8	1
492	Proteomic profiling of phosphatidylinositol 3-kinase (PI3K) altered metastatic colorectal cancer (mCRC) after protein kinase B (Akt) inhibition: Insulin like growth factor 1 receptor (IGF1R) mediates adaptive resistance.. Journal of Clinical Oncology, 2018, 36, 3549-3549.	0.8	1
493	Circulating tumor DNA profiling to identify patients with metastatic colorectal cancer with improved overall survival following Sym004 treatment.. Journal of Clinical Oncology, 2018, 36, e15577-e15577.	0.8	1
494	Preclinical development of tumor-infiltrating lymphocyte therapy for metastatic colorectal cancer.. Journal of Clinical Oncology, 2018, 36, 95-95.	0.8	1
495	Relative impact of chemotherapy with or without bevacizumab on cytokines and angiogenic factors (CAFs) in metastatic colorectal cancer.. Journal of Clinical Oncology, 2011, 29, 401-401.	0.8	1
496	Preoperative radiation therapy with concurrent capecitabine, bevacizumab, and erlotinib for rectal adenocarcinoma: A phase I trial.. Journal of Clinical Oncology, 2012, 30, 544-544.	0.8	1
497	Association of CpG island methylator phenotype (CIMP) with inferior progression-free survival with anti-EGFR monoclonal antibody therapy in metastatic colorectal cancer.. Journal of Clinical Oncology, 2014, 32, 3633-3633.	0.8	1
498	Predictors of clonal evolution in metastatic colorectal cancer patients.. Journal of Clinical Oncology, 2015, 33, 3604-3604.	0.8	1
499	Low frequency <i>KRAS</i> G12/13 mutations in urine cell-free (cf) DNA from patients with <i>BRAF</i> V600E-mutant advanced cancers.. Journal of Clinical Oncology, 2015, 33, 11048-11048.	0.8	1
500	Abstract 3146: Circulating tumor DNA assay performance for detection and monitoring of <i>KRAS</i> mutations in urine from patients with advanced cancers. , 2016, , .		1
501	Abstract 2632: Clinical validation of circulating DNA analysis for the detection of point mutations and of the longitudinal metastatic colorectal patient follow up for detecting emergence of resistance to targeted therapy. , 2016, , .		1
502	Abstract A167: Targeting HER2 (ERBB2) amplification identified by next-generation sequencing (NGS) in patients with advanced or metastatic solid tumors. , 2018, , .		1
503	Effect of matched therapy in metastatic colorectal cancer on progression free survival in the phase I setting.. Journal of Clinical Oncology, 2018, 36, 3522-3522.	0.8	1
504	Comprehensive landscape of gene amplifications (amps) in tissue and circulating tumor DNA (ctDNA) in metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 2019, 37, 604-604.	0.8	1

#	ARTICLE	IF	CITATIONS
505	Quantifying the evolution of tumor architecture using serial circulating tumor DNA.. Journal of Clinical Oncology, 2019, 37, 600-600.	0.8	1
506	Phase II/III study of circulating tumor DNA as a predictive biomarker in adjuvant chemotherapy in patients with stage II colon cancer: NRG-GI005 (COBRA).. Journal of Clinical Oncology, 2022, 40, TPS233-TPS233.	0.8	1
507	First-in-human phase 1/2 study of autologous T cells engineered using the Sleeping Beauty System transposon/transposase to express T-cell receptors (TCRs) reactive against cancer-specific mutations in patients with advanced solid tumors.. Journal of Clinical Oncology, 2022, 40, TPS2679-TPS2679.	0.8	1
508	Aggressive Combined Modality Therapy for Recurrent Colorectal Cancer Involving the Duodenum and Pancreas: A Report of 5 Cases. Clinical Colorectal Cancer, 2008, 7, 338-342.	1.0	0
509	Reply to N. Personeni et al. Journal of Clinical Oncology, 2011, 29, 2734-2735.	0.8	0
510	61 Patient-derived Metastatic Colorectal Cancer Mouse Tumorgrafts for Anticancer and Mechanism Studies. European Journal of Cancer, 2012, 48, 20-21.	1.3	0
511	Survival Outcomes in Metastatic Colorectal Cancer (CRC) with High-Level Microsatellite Instability (MSI-H). Annals of Oncology, 2012, 23, ix220-ix221.	0.6	0
512	BRAF Mutations in Non-Metastatic Colorectal Cancer: Current Relevance and Future Implications. Current Colorectal Cancer Reports, 2015, 11, 303-310.	1.0	0
513	Addition of RAS Mutation Status May Strengthen the Predictive Model for Progression of Indeterminate Pulmonary Nodules. Annals of Surgery, 2016, 264, e7.	2.1	0
514	Clinical Utility of Biocartis Idylla in Colorectal Cancer Patients' Tissue and Plasma. Cancer Genetics, 2016, 209, 293.	0.2	0
515	Hyperfractionated Accelerated Reirradiation for Rectal Cancer: A Large Single-Institution Retrospective Analysis. International Journal of Radiation Oncology Biology Physics, 2016, 96, S105.	0.4	0
516	Integrated safety summary (ISS) for trifluridine/tipiracil (TAS-102). Annals of Oncology, 2016, 27, vi183.	0.6	0
517	219 RAS Mutation Status Impacts Survival in Patients Undergoing Repeat Hepatectomy for Colorectal Liver Metastases. Gastroenterology, 2016, 150, S1174.	0.6	0
518	Variability of current global practice patterns in the management of metastatic colorectal cancer. Annals of Oncology, 2018, 29, v73.	0.6	0
519	Triple blockade of EGFR, MEK and PD-L1 as effective antitumor treatment in PD-L1 overexpressing, MEK inhibitor resistant colon cancer cells. Annals of Oncology, 2019, 30, v4.	0.6	0
520	Immune competent somatic mosaic model of colorectal cancer. Annals of Oncology, 2019, 30, v505.	0.6	0
521	Is the Patient Cured?. JAMA Oncology, 2019, 5, 1695.	3.4	0
522	Real-time Interrogation of Aspirin Reactivity, Biochemistry, and Biodistribution by Hyperpolarized Magnetic Resonance Spectroscopy. Angewandte Chemie, 2019, 131, 4223-4227.	1.6	0

#	ARTICLE	IF	CITATIONS
523	489P Somatic mosaic model of colorectal cancer for translational immune cancer research. <i>Annals of Oncology</i> , 2020, 31, S448.	0.6	0
524	Clinical Associations of Treatment Failure After Radiation Therapy for Colorectal Liver Metastases. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, E53-E54.	0.4	0
525	SO-21 Management of adverse events associated with encorafenib plus cetuximab in patients with BRAF V600E-mutant metastatic colorectal cancer (The BEACON CRC Study). <i>Annals of Oncology</i> , 2020, 31, S224-S225.	0.6	0
526	Epigenetic regulation of the Wnt-signaling pathway in CIMP-H BRAFV600E mCRC.. <i>Journal of Clinical Oncology</i> , 2021, 39, 110-110.	0.8	0
527	A novel clinical tool to estimate risk of false negative KRAS mutation in circulating tumor DNA testing.. <i>Journal of Clinical Oncology</i> , 2021, 39, 3594-3594.	0.8	0
528	P-45 An open-label, phase 2 study of patritumab deruxtecan in patients with previously treated advanced/metastatic colorectal cancer. <i>Annals of Oncology</i> , 2021, 32, S111.	0.6	0
529	Benchmarking Outcomes for Definitive Treatment of Young-Onset, Locally Advanced Rectal Cancer. <i>Clinical Colorectal Cancer</i> , 2021, , .	1.0	0
530	Systemic Therapy for Non-operable Colorectal Cancer Metastases. , 2009, , 1-8.		0
531	Survival advantage associated with palliative oophorectomy in patients with metastatic colorectal cancer (CRC) to the ovaries (mCRC-O): A single institution retrospective analysis.. <i>Journal of Clinical Oncology</i> , 2011, 29, 539-539.	0.8	0
532	Association of circulating cytokine and angiogenic factors (CAFs) with outcomes to second-line FOLFOX plus bevacizumab or cediranib in metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2011, 29, 406-406.	0.8	0
533	Association of PTEN loss and local recurrence in stage II-III colon cancer.. <i>Journal of Clinical Oncology</i> , 2011, 29, 399-399.	0.8	0
534	A multicenter, multinational retrospective analysis of mitomycin C (MMC) in refractory metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2011, 29, 3577-3577.	0.8	0
535	High-grade neuroendocrine carcinomas (HGNECs) of the colon and rectum: A single-institution retrospective analysis.. <i>Journal of Clinical Oncology</i> , 2011, 29, e14040-e14040.	0.8	0
536	Prognostic effects of circulating markers of epithelial mesenchymal transition (EMT) in metastatic colorectal cancer patients.. <i>Journal of Clinical Oncology</i> , 2012, 30, 456-456.	0.8	0
537	A phase I/II study of azacitidine and capecitabine/oxaliplatin (CAPOX) in refractory metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2012, 30, 450-450.	0.8	0
538	Systematic survey of therapeutic trials for metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2012, 30, 523-523.	0.8	0
539	Relationship of Src activity and prior oxaliplatin on outcomes after hepatectomy for metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2012, 30, 3561-3561.	0.8	0
540	Progression-free survival in metastatic, BRAF-mutated colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2013, 31, 458-458.	0.8	0

#	ARTICLE	IF	CITATIONS
541	Molecular characteristics of complete PTEN loss in metastatic colorectal cancer.. Journal of Clinical Oncology, 2013, 31, 389-389.	0.8	0
542	Association of colorectal cancer intrinsic subtypes with prognosis, chemotherapy response, deficient mismatch repair, and epithelial to mesenchymal transition (EMT).. Journal of Clinical Oncology, 2013, 31, 3530-3530.	0.8	0
543	Abstract B35: Acquired KRAS mutations after anti-EGFR therapy partially derive from low-frequency clones detectable in the primary tumor.. , 2013, , .		0
544	Association of prior treatment with anti-EGFR monoclonal antibodies with downregulation of circulating TRAIL and upregulation of EGFR and VEGF family ligands in metastatic colorectal cancer.. Journal of Clinical Oncology, 2014, 32, 452-452.	0.8	0
545	Colorectal high-grade neuroendocrine carcinoma: A single institution experience.. Journal of Clinical Oncology, 2014, 32, 540-540.	0.8	0
546	Il-8 as an underutilized prognostic factor in metastatic colorectal cancer.. Journal of Clinical Oncology, 2014, 32, 409-409.	0.8	0
547	Association between KRAS mutation and lung metastasis in advanced colorectal cancer.. Journal of Clinical Oncology, 2014, 32, 494-494.	0.8	0
548	Efficiency of biomarker screening for enriched metastatic colorectal cancer trials: The ATTACC program experience.. Journal of Clinical Oncology, 2014, 32, 450-450.	0.8	0
549	Abstract 4276: T200: a high depth targeted exome sequencing platform to identify actionable alterations in FFPE solid tumor samples. , 2014, , .		0
550	Next-generation sequencing of advanced, relapsed colorectal adenocarcinoma (CRC) to reveal mutations affecting Wnt, MAPK and PI3K pathway signaling: Emergence of novel combinatorial strategies.. Journal of Clinical Oncology, 2015, 33, 605-605.	0.8	0
551	Multiple independent methods fail to confirm MET amplification rate reported in literature for metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 2015, 33, 572-572.	0.8	0
552	Acquired mutations in MAPK signaling pathway following initial pharmacological response in BRAF-mutated metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 2015, 33, 629-629.	0.8	0
553	Proteomic signatures of colorectal cancer to identify distinct and reproducible subgroups independent of oncogenic mutations.. Journal of Clinical Oncology, 2015, 33, 580-580.	0.8	0
554	Proteomic signatures of colorectal cancer to identify distinct and reproducible subgroups and to reflect prognosis.. Journal of Clinical Oncology, 2015, 33, 3612-3612.	0.8	0
555	A phase II study of nab-paclitaxel in refractory CIMP-high metastatic colorectal cancer.. Journal of Clinical Oncology, 2015, 33, e14700-e14700.	0.8	0
556	Clinical utility of a circulating cell-free DNA assay for clinical trial enrollment in refractory metastatic colorectal cancer patients.. Journal of Clinical Oncology, 2015, 33, 3601-3601.	0.8	0
557	Recurrent parathyroid carcinoma and the need for molecular profiling to aid in prognostication and therapeutics.. Journal of Clinical Oncology, 2015, 33, e17012-e17012.	0.8	0
558	Abstract 4263: Concurrent aberrations in the Wnt, MAPK and PI3K pathways identified through next generation sequencing of relapsed refractory colorectal adenocarcinoma (CRC): Implications for future therapeutic trials. , 2015, , .		0

#	ARTICLE	IF	CITATIONS
559	Abstract 603: Consensus molecular subtyping through a community of experts advances unsupervised gene expression-based disease classification and facilitates clinical translation. , 2015, , .		0
560	Abstract 4763: Correlation of CpG island methylation with clinical and pathologic characteristics in metastatic colorectal cancer patients. , 2015, , .		0
561	Abstract 869: Body mass index, weight gain, and physical activity during adulthood in relation to colorectal cancer risk. , 2015, , .		0
562	Abstract 2407: MultiplexKRASG12/G13 mutation testing of 16ng of unamplified cell-free DNA from plasma of patients with advanced cancers using Droplet Digital PCR. , 2015, , .		0
563	Abstract 3737: Severe obesity and colorectal cancer patient survival. , 2015, , .		0
564	Abstract 5236: Prospective clinical application of circulating cell-free DNA sequencing in metastatic colorectal cancer. , 2015, , .		0
565	Abstract 3704: Demographics of colorectal cancer patients vary by aspirin use. , 2015, , .		0
566	Phase II study of bevacizumab combined with capecitabine and oxaliplatin in patients with advanced adenocarcinoma of the small bowel or ampulla of vater.. Journal of Clinical Oncology, 2016, 34, 144-144.	0.8	0
567	Association of FBXW7 missense mutations (mt) with unfavorable prognosis in metastatic colorectal cancer (mCRC) patients (pts).. Journal of Clinical Oncology, 2016, 34, 3607-3607.	0.8	0
568	Identification of novel <i>EGFR</i> ectodomain mutations based on a large database of clinical circulating cell-free DNA sequencing tests.. Journal of Clinical Oncology, 2016, 34, e23167-e23167.	0.8	0
569	Abstract 143: Mutational landscape of colorectal adenomas reveals potential signatures for progression. , 2016, , .		0
570	Abstract 3815: Cyclin-dependent kinase 9: a potential therapeutic target for esophageal adenocarcinoma. , 2016, , .		0
571	Abstract IA21: Opportunities for integration of PDX models into clinical trials. , 2016, , .		0
572	Arginine methylation of EGFR in circulating tumor cells: A new biomarker for predicting resistance to anti-EGFR agents.. Journal of Clinical Oncology, 2017, 35, 3590-3590.	0.8	0
573	DNA sequencing of the small bowel adenocarcinomas to identify targetable ErbB2 mutations.. Journal of Clinical Oncology, 2017, 35, e15800-e15800.	0.8	0
574	Molecular characterization of TP53 mutations and copy number change in colorectal cancers.. Journal of Clinical Oncology, 2017, 35, e15143-e15143.	0.8	0
575	Liquid biopsies of plasma exosomal nucleic acids, plasma cell-free DNA, and survival of patients with advanced cancers.. Journal of Clinical Oncology, 2017, 35, 11551-11551.	0.8	0
576	Simultaneous molecular alterations in solid tumors with IDH1 or IDH2 mutations.. Journal of Clinical Oncology, 2017, 35, 11609-11609.	0.8	0

#	ARTICLE	IF	CITATIONS
577	Abstract 2924: Circulating DNA demonstrates convergent evolution and common resistance mechanisms during treatment of colorectal cancer. , 2017, , .		0
578	Abstract 642: Detection of circulating antibodies against KRAS in patients with advanced cancers. , 2017, , .		0
579	Abstract 4742:APCWT/RASWT/BRAFWTumors represent an under recognized poor prognostic group of right sided colorectal cancer. , 2017, , .		0
580	Abstract A055: RSPO3 overexpression is a characteristic feature of signet ring gastrointestinal malignancies. , 2018, , .		0
581	Clinical and molecular characterization of early-onset colorectal cancer patients with inflammatory bowel disease.. Journal of Clinical Oncology, 2018, 36, 689-689.	0.8	0
582	Association of SMAD4 gene mutation with incidence of peritoneal involvement in unresectable metastatic colorectal cancer.. Journal of Clinical Oncology, 2018, 36, 772-772.	0.8	0
583	Effect of matched therapy in metastatic colorectal cancer on progression free survival in the phase I setting.. Journal of Clinical Oncology, 2018, 36, 619-619.	0.8	0
584	Predictors for detecting circulating tumor DNA (ctDNA) in metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 2018, 36, 634-634.	0.8	0
585	Malignant peritoneal mesothelioma: Clinicopathological features, prognostic factors, and survival outcomes.. Journal of Clinical Oncology, 2018, 36, 650-650.	0.8	0
586	Consensus molecular subtypes (CMS), markers of systemic inflammation (SI) and clinicopathological parameters in colorectal cancer (CRC).. Journal of Clinical Oncology, 2018, 36, e15600-e15600.	0.8	0
587	Refining the use of adjuvant oxaliplatin in clinical stage II or III rectal adenocarcinoma.. Journal of Clinical Oncology, 2018, 36, e15686-e15686.	0.8	0
588	Abstract 4904: PD-L1 pathway activation as an escape mechanism of resistance to MEK inhibitor treatment in human colorectal cancer models. , 2018, , .		0
589	Systematic review of three decades of clinical trials in metastatic colorectal cancer: Making lemonade out of lemons?. Journal of Clinical Oncology, 2019, 37, 656-656.	0.8	0
590	Population pharmacokinetics (popPK) of Sym004 to evaluate the effect of intrinsic and extrinsic factors on exposure in metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 2019, 37, 496-496.	0.8	0
591	Prediction model for detecting circulating tumor DNA (ctDNA) in metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 2019, 37, 3590-3590.	0.8	0
592	The association between female hormonal supplementation and molecular types in colorectal cancer.. Journal of Clinical Oncology, 2019, 37, e15133-e15133.	0.8	0
593	Evaluation of complete pathological remission rates in surgically resected MSI-high metastatic colorectal cancers (mCRC).. Journal of Clinical Oncology, 2019, 37, e15046-e15046.	0.8	0
594	FOLFOXIRI versus doublet-regimens in the first-line therapy of MSI-S right-sided (RS) metastatic colorectal cancer (mCRC): A survival analysis.. Journal of Clinical Oncology, 2019, 37, e15060-e15060.	0.8	0

#	ARTICLE	IF	CITATIONS
595	Identifying anti-EGFR (EGFRi) response subgroups using evidence of ctDNA selective pressure.. Journal of Clinical Oncology, 2019, 37, 3587-3587.	0.8	0
596	Reporting of patient (pt) characteristics (c) and use of stratification factors (SF) in phase III trials for metastatic colorectal cancer (mCRC): Urgent need for standardization.. Journal of Clinical Oncology, 2019, 37, e15055-e15055.	0.8	0
597	Meat consumption and BRAF mutation status in colorectal cancer.. Journal of Clinical Oncology, 2019, 37, e15135-e15135.	0.8	0
598	Association between gene fusions and anti-EGFR resistance signature in colorectal cancer.. Journal of Clinical Oncology, 2019, 37, 3564-3564.	0.8	0
599	Abstract 3162: Prognostic value of tumor mutational burden using a 409 gene NGS panel in cancer patients with advanced stage recurrent or treatment refractory disease. , 2019, , .		0
600	Abstract B003: Combinatorial therapies of neratinib for HER2-amplified cancer. , 2019, , .		0
601	Abstract C080: The combination of MEK and MDM2 inhibitors demonstrates promising antitumor efficacy in MAPK altered patient-derived thyroid and colorectal cancer models. , 2019, , .		0
602	Abstract CT061: Binimetinib in patients with tumors with NRAS mutations: NCI-MATCH ECOG-ACRIN Cancer Research Group subprotocol EAY131-Z1A. , 2020, , .		0
603	Abstract 3172: Evaluation of cytotoxic T cell infiltration and clinical benefit from PD-L1 checkpoint inhibition among PIK3CA mutant microsatellite stable (MSS) metastatic adenocarcinoma patients. , 2020, , .		0
604	Abstract 808: Analysis of 1151 prospective research biopsies: Factors influencing tumor yield across patients and biopsy cores. , 2020, , .		0
605	Abstract 1: Sulindac plus phospholipid is effective for polyp reduction and safer than sulindac alone. , 2020, , .		0
606	Abstract NG14: Proteome instability is an immunogenic therapeutic vulnerability in mismatch repair deficient cancer. , 2020, , .		0
607	Clinical Applications of Liquid Biopsies in Gastrointestinal Oncology. Gastrointestinal Cancer Research: GCR, 2014, 7, S8-S12.	0.8	0
608	Novel targets for systemic therapy of colorectal cancer. Clinical Advances in Hematology and Oncology, 2008, 6, 38-40.	0.3	0
609	BASECAMP-1: Leveraging human leukocyte antigen (HLA) loss of heterozygosity (LOH) in solid tumors by next-generation sequencing (NGS) to identify patients with relapsed solid tumor for future logic-gated Tmod CAR T-cell therapy.. Journal of Clinical Oncology, 2022, 40, TPS2676-TPS2676.	0.8	0
610	Reply to F. Dayyani et al. JCO Precision Oncology, 2022, , .	1.5	0